www.pwc.com.br

(A free translation of the original in Portuguese)

Diagnósticos da América S.A.

Parent company and consolidated financial statements at December 31, 2024 and independent auditor's report

(A free translation of the original in Portuguese)

Independent auditor's report

To the Board of Directors and Shareholders
Diagnósticos da América S.A.

Opinion

We have audited the accompanying parent company financial statements of Diagnósticos da América S.A. ("DASA" or "Company"), which comprise the balance sheet as at December 31, 2024 and the statements of income, comprehensive income, changes in equity and cash flows for the year then ended, as well as the accompanying consolidated financial statements of Diagnósticos da América S.A. and its subsidiaries ("Consolidated"), which comprise the consolidated balance sheet as at December 31, 2024 and the consolidated statements of income, comprehensive income, changes in equity and cash flows for the year then ended, and notes to the financial statements, including material accounting policies and other explanatory information.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Diagnósticos da América S.A. and of Diagnósticos da América S.A. and its subsidiaries as at December 31, 2024, and the financial performance and the cash flows for the year then ended, as well as the consolidated financial performance and the cash flows for the year then ended, in accordance with accounting practices adopted in Brazil and with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) (currently named by the IFRS Foundation as "IFRS accounting standards").

Basis for opinion

We conducted our audit in accordance with Brazilian and International Standards on Auditing. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Parent Company and Consolidated Financial Statements section of our report. We are independent of the Company and its subsidiaries in accordance with the ethical requirements established in the Code of Professional Ethics and Professional Standards issued by the Brazilian Federal Accounting Council, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

PricewaterhouseCoopers Auditores Independentes Ltda.
Av. Marcos Penteado de Ulhoa Rodrigues, 939, 12º,
Torre Jatobá, Castelo Branco Office Park, Barueri, SP,
Brasil, 06460-040
T: +55 (11) 4004-8000

Diagnósticos da América S.A.

Key Audit Matters

Key Audit Matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current year. These matters were addressed in the context of our audit of the parent company and consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.



Why it is a Key Audit Matter	How the matter was addressed in the audit
Financial information system	
The operations of the Company and its subsidiaries are impacted by the high number of transactions, geographic dispersion and the particularities of its business units acquired over time. The structure of the financial information system is complex and includes internal controls and general Information Technology controls, manual and automated, dependent on integrated management systems or not. We considered this circumstance as one of the key matters in our audit, since transactions processed in different automated systems may result in incorrect critical information, including that used in the preparation of the parent company and consolidated financial statements.	Our procedures included, among others: We updated our understanding of the systems and effectiveness of the main internal controls and general Information Technology controls used to generate financial information, to determine the nature, extent and timing of our audit procedures. We used Information Technology experts to assist us in understanding the environments of the automated information systems, as well as the manual controls dependent on the automated systems. We performed substantive tests on the integrity of the reports produced by the related systems and used in our audit procedures. In our audit process, we identified recommendations for improving the accounting and internal control systems and communicated them to management and those charged with governance. For the aspects observed in relation to the internal controls and general Information Technology controls, we assessed the impact on the nature, timing and extent of our substantive procedures to obtain sufficient and appropriate evidence.

Diagnósticos da América S.A.

Why it is a Key Audit Matter	How the matter was addressed in the audit
At December 31, 2024, the Company and its subsidiaries have relevant balances of intangible assets, which include goodwill on the acquisition of companies, whose recoverable value is tested annually, as required by CPC 01/IAS 36 - "Impairment of Assets". The recoverability assessment is performed for each segment and Cash Generating Unit (CGU) to which the balances relate whose value in use is based on estimated future cash flows, discounted at present value, involving assumptions for the preparation of cash flow projections, including the business growth rate and the discount rate used to discount projected cash flows. Considering the uncertainties related to the assumptions used to estimate the value in use of the CGU, which could result in a material adjustment to the accounting balances, we maintained this as an area of focus in our audit work.	Our audit procedures included, among others: • Understanding of the process of preparation and revision of technical studies and analyses of the recoverable value prepared by the Company and its subsidiaries; • Assessment of governance around this process, including confirmation of approval of the budgets used in the impairment calculations. • Analysis, with the assistance of our specialists, of the assumptions used by the Company and its subsidiaries, especially those related to business growth rates, cash flow projections and the respective weighted average cost of capital, as well as a comparison of the assumptions used by the Company and its subsidiaries with market data, when available. • Analysis of disclosures made by the Company in the parent company and consolidated financial statements. We consider that the criteria and assumptions adopted by management of the Company and its subsidiaries to determine the recoverable value of these assets, as well as the disclosures in the explanatory notes, are consistent with the evidence obtained.
Tax, social security, labor and civil provisions and contingencies (Note 20)	
The Company and its subsidiaries are defendants in lawsuits arising from the normal course of their operations, especially of a tax, social security, labor and civil nature, which are related to divergences in the interpretation of standards and legislation, among others. Normally, such lawsuits are closed after a long time and involve not only discussions on the merits, but also complex procedural aspects, pursuant to the current legislation. The management of the Company and its subsidiaries, with the support of its internal and external legal counsel, estimates the possible outcomes for these lawsuits, records a provision for those considered as probable losses, and discloses those considered as a possible loss.	Our audit procedures included, among others, understanding the controls established to identify, measure, record and disclose provisions and contingencies. We obtained from the legal counsel who defend the tax, social security, labor and civil claims of the Company and its subsidiaries the confirmation of the values and the classification of the risk of losses. With the support of our Tax specialists, we obtained an understanding of the matters of the main ongoing lawsuits, obtained supporting documentation for management's assessment, and analyzed and discussed the reasonableness of the conclusions reached.

Why it is a Key Audit Matter	How the matter was addressed in the audit
Considering the relevance of the amounts, the uncertainties involved in determining and forming the provision for contingencies, as well as the required disclosures, we maintained this a key audit focus.	We consider that the criteria and assumptions adopted by management to determine and record the provision for contingencies, as well as the disclosures made in the explanatory notes, are consistent with the assessments of its legal counsel.

Other matters

Statements of Value Added

The parent company and consolidated Statements of Value Added for the year ended December 31, 2024, prepared under the responsibility of the Company's management and presented as supplementary information for IFRS purposes, were submitted to audit procedures performed in conjunction with the audit of the Company's financial statements. For the purposes of forming our opinion, we evaluated whether these statements are reconciled with the financial statements and accounting records, as applicable, and if their form and content are in accordance with the criteria defined in Technical Pronouncement CPC 09 - "Statement of Value Added". In our opinion, these statements of value added have been properly prepared, in all material respects, in accordance with the criteria established in the Technical Pronouncement, and are consistent with the parent company and consolidated financial statements taken as a whole.

Other information accompanying the parent company and consolidated financial statements and the auditor's report

The Company's management is responsible for the other information that comprises the Management Report.

Our opinion on the parent company and consolidated financial statements does not cover the Management Report, and we do not express any form of audit conclusion thereon.

In connection with the audit of the parent company and consolidated financial statements, our responsibility is to read the Management Report and, in doing so, consider whether this report is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement in the Management Report, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the parent company and consolidated financial statements

Management is responsible for the preparation and fair presentation of the parent company and consolidated financial statements in accordance with accounting practices adopted in Brazil and with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) (currently named by the IFRS Foundation as "IFRS accounting standards"), and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company and consolidated financial statements, management is responsible for assessing the ability of the Company and its subsidiaries, as a whole, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company and its subsidiaries, as a whole, or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the financial reporting process of the Company and its subsidiaries.

Auditor's responsibilities for the audit of the parent company and consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the parent company and consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Brazilian and International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Brazilian and International Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the parent company and consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control of the Company and its subsidiaries.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company and its subsidiaries, as a whole, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the parent company and consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company and its subsidiaries to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the parent company and consolidated financial statements, including the disclosures, and whether these financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis to form an opinion on the parent company and consolidated financial statements. We are responsible for the direction, supervision and review of the audit work performed for the purpose of the group audit. We remain solely responsible for our audit opinion.

Diagnósticos da América S.A.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and, where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current year and are therefore the Key Audit Matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Barueri, March 26, 2025

PricewaterhouseCoopers
Auditores Independentes Ltda.
CRC 2SP027083/F-3

Carlos Eduardo Guaraná Mendonça
Contador CRC 1SP196994/O-2

Financial Statements 2024

Dear shareholders,
The Management of DIAGNÓSTICOS DA AMÉRICA S.A. (B3: DASA3) ("Company" or "Dasa") is pleased to submit its Management Report and Financial Statements for the year 2024, prepared in accordance with Brazilian corporate law and accompanied by the unqualified Report of the Independent Auditors.

Company's profile

Dasa is one of the largest integrated healthcare networks in Brazil, with over 48,000 employees and 250 partner doctors. The Company is part of the lives of over 23 million people per year, with recognized medical and patient care standards.

The Company is organized into two business units: Hospitals and Oncology (BU1) and Diagnostic Medicine (BU2).

In the Hospitals and Oncology business unit, Company has 16 hospitals in Brazil, which total 3,434 beds. There were over 856 patient-days in our operations in 2024, resulting in an average occupancy rate of 79.5% for the year.

In Diagnostic Medicine, there are over 850 units throughout Brazil and Argentina. In 2024, 414 million medical examinations/ tests were performed across our network, a growth of 5%.

Financial and operational information

The financial information presented herein was extracted from the financial statements for the year ended December 31, 2024, prepared in accordance with accounting practices adopted in Brazil and the International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB) and presented in accordance with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of financial statements (the "Standardized Financial Statements – DFP"). The financial and operational information included in this earnings discussion is subject to rounding off. Therefore, the total amounts presented in the tables and charts may differ from the direct numerical aggregation of the amounts that precede them. The sum of the financial information of the business units may not correspond to the Company's consolidated financial information, due to the elimination of transactions between segments, with no effect on EBITDA and net income. The information referred to as EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is presented according to Resolution 156 issued by CVM on June 23, 2022.

Operational environment and highlights for the year

The year 2024 marks the beginning of a transformation process for Dasa, seeking a more economically robust and profitable company, based on its recognized medical and patient care standards. During the year, we laid the foundations for a strategic, operational and financial repositioning the Company, with greater focus on its core activities of diagnostic medicine and hospitals/oncology, implementation of an operational excellence program and initiatives to reduce the Company's leverage.

On the strategic front, we announced the signing of the Association Agreement with Amil in June 2024, which will create one of the largest hospital groups in Brazil. Amil will contribute hospital and oncology operations to Ímpar, Dasa's hospital and oncology company, thus making Ímpar a joint venture, with equal equity interests of 50% of the voting capital held by each of Amil and Dasa. By joining forces, Ímpar will become a more robust and attractive non-verticalized network of hospitals, with the capacity to offer more options of facilities, healthcare professionals and treatments, with a total of 25 hospitals and 4,500 beds, mostly located in São Paulo, Rio de Janeiro and the Federal District.

As part of the execution strategy with focus on the core activities of diagnostics and hospitals/oncology, we completed the sale of Dasa Empresas in December 2024, the Company's insurance brokerage and consulting business, which recorded a negative EBITDA of R$ 12 million in 2024. The total value of the sale of Dasa Empresas was R$ 255 million, of which R$ 195 million was received upon closing, R$ 10 million within 12 months of the closing date (subject to the usual cash/debt adjustment) and R$ 50 million of potential earn-out over five years.

We started implementing a wide-ranging operational excellence program, with emphasis on (i) relocating and reducing occupied administrative buildings, (ii) reorganizing the personnel structure and adapting human resources policies to the market, (iii) reducing unprofitable diagnostic service units and consolidating technical operational centers, (iv) increasing standardization of surgical hours, medical teams, medical materials and medicines in hospitals, and (v) strengthening processes and controls in general. At the same time, we achieved better NPS levels in 2024 than last year, once again receiving recognition from our patients for the services we provide and thus demonstrating a positive relationship between operational efficiency and quality medicine.

The initial benefits of this operational excellence program were fundamental in counteracting the significant challenges faced in the economic and operational environment. Regarding paying sources, there has been an increase in demands for de-accreditation and bundling, as well as greater initial disallowances, discounts and payment deadlines. In the economic environment, we saw rising inflation and the impact of the implementation of the new nursing legislation, which increased our operating costs and expenses.

In this challenging environment and supported by the initiatives of the operational excellence program, we will close 2024 with gross operating income 8% higher than in 2023 and EBITDA growth of 11%.

As planned, we also made progress on the operational front of the Ímpar hospitals that will be part of the Amil transaction. We estimate that the pro-forma EBITDA of the operations that are part of the Association Agreement, including those of Ímpar and Amil, are R$ 998 million in 2024, which accounts for a growth of 28% compared to 2023 and a pro-forma EBITDA margin 1.4 p.p. higher. With this growth in results in 2024 and the net debt (including acquisitions payable and installment payment of taxes) expected to close at R$ 3.15 billion, we estimate a proforma net debt/EBITDA ratio at the formation of the new company of 3.16x, significantly lower than the proforma debt of 5.0x when the transaction was announced. Following closing, we will be able to start realizing the synergies of the joint operation, thus driving the evolution of results and reducing the leverage of the new company.

As to the capital structure, we witnessed important changes in the Company's indebtedness during the year, leading to a reduction in the net financial debt after acquisitions payable and prepayment of receivables / EBITDA ratio from 4.90x in December 2023 to 4.08x in December 2024.

In June, the Company received an advance for capital increase from its controlling shareholders in the amount of R$ 1.5 billion, improving our liquidity and optimizing timings for operational deleveraging initiatives. As part of this approach, we invested R$ 547 million in 2024, 25% lower than in 2023 and 43% lower than in 2022, mainly in technology and expansion, and established new processes that have allowed stability in the average collection period since the second quarter. Excluding the effect of the advance for future capital increase, net financial debt after acquisitions payable and prepayment of receivables was practically stable in 2Q24, the best performance since the capital reopening in 2Q21, and has since been on a downward trend as results improved, a lower level of investments and working capital management.

In 2024, we began transforming Dasa through many initiatives, with an eye on the future, always optimistic as to the path required to make Dasa an increasingly solid, profitable and long-lived company, recognized for its quality medicine by the medical community and its patients.

The main events during the year and subsequent events are listed, respectively, in Notes 2 and 34 to these Financial Statements.

At this time of intense transformation, we would like to thank all our employees, stakeholders, investors and the market in general for their dedication, trust and partnership.

EXECUTIVE BOARD.

Operating and financial performance

(R$ million)	2023	2024	Δ
Consolidated gross income	**15,557**	**16,800**	**8%**
Gross income BU1	8,067	8,628	7%
Gross income BU2	7,490	8,191	9%
Deductions and taxes levied	(1,305)	(1,478)	13%
Consolidated net income	**14,252**	**15,322**	**8%**
Cost of services	(10,365)	(11,129)	7%
Gross profit	**3,887**	**4,193**	**8%**
General and administrative expenses	(2,975)	(3,187)	7%
Other income and (expenses), net	2	87	5296%
Profit before financial result and income tax and social contribution	**913**	**1,094**	**20%**
Financial income (expenses), net	(1,909)	(2,161)	13%
Profit (loss) before income tax and social contribution	**(996)**	**(1,067)**	**7%**
Income tax and social contribution	(134)	(129)	-4%
Profit (loss) from continuing operation for the year	**(1,130)**	**(1,196)**	**6%**
(+) Financial income /expenses, net	1,909	2,161	13%
(+) Income tax and social contribution	134	129	-4%
(+) Depreciation and Amortization	1,296	1,367	5%
EBITDA	**2,210**	**2,461**	**11%**
EBITDA Margin %	*15.5%*	*16.1%*	*0.6 p.p.*

Gross and net operating income

In 2024, the Company's gross income totaled R$ 16.800 billion, a 8% increase compared to the previous year, with similar growth in both business units.

In Hospitals and Oncology, gross income in 2024 grew 7% compared to 2023, due to a 2% increase in the number of patient-days and a 5% higher average ticket, both driven by the discontinuation of certain less profitable operations and a better mix of procedures.

Operational indicators - BU1 (Hospitals and Oncology)



¹BU1's average ticket = BU1's gross revenue / number of patients-day

In Diagnostics, gross income in 2024 grew 9%, being domestic (+5%) and international operations (+149%), driven by a higher volume of tests and the exchange rate effect of accounting of Argentina being in a hyperinflationary economy.

Operating indicators – BU2 (Diagnoses)



¹ BU2's average ticket = BU2's gross revenue (excluding care coordination) / number of exams.

The Company's net income was R$ 15.322 billion in 2024, an increase of 8% compared to 2023, in line with gross income and influenced by the same factors.

Costs of services rendered and gross profit

The costs of services rendered in 2024 totaled R$ 11.129 billion, 7% higher than in 2023, but lower than the 8% increase in income. As a result, gross profit grew R$ 306 million (+8%) in 2024 compared to 2023.

The following factors contributed to gross profit: (i) the higher volume of operations in both business units, (ii) the initial benefits of the operational excellence program and (iii) the combined impact of foreign exchange and hyperinflationary accounting on the Argentine operation at the end of 2023, which partially offset the cost increases resulting from rising inflation and the implementation of the new nursing legislation.

General and administrative expenses and other income and (expenses), net

In 2024, total expenses amount to R$ 3.100 billion, an increase of 4% compared to 2023, lower than the accumulated inflation, reflecting the Company's progress in reviewing its management processes and organizational structure.

Financial income (expense)

In 2024, the net Financial income (expense) was an expense of R$ 2.161 billion vs. financial expense of R$ 1.909 billion in 2023, mainly due to the higher interest rate on debt and the marking to market of the hedging instruments contracted to exchange debentures with fixed rates and inflation indexes to the floating Interbank Deposit Certificate (CDI) rates.

Net profit (loss)

The loss from continuing operations in 2024 was R$ 66, million higher than the 2023 loss, mainly as a result of the above-mentioned financial income (expense).

EBITDA

EBITDA totaled R$ 2.461 billion in 2024, an increase of 11% compared to the same period of 2023, thus leading to an increase of 0.6 p.p. in the EBITDA margin. This EBITDA expansion is due to the higher volume of operations and the initial benefits of the operational excellence program, which mitigated the effects of the higher level of disallowances and higher expenses resulting from the new nursing legislation and inflation over the last 12 months.

Cash position and indebtedness

The Company ended 2024 with a net financial debt after acquisitions payable and prepaid receivables of R$ 10.1 billion, R$ 775 million lower than at the end of 2023. At the end of 2024, the gross financial debt was R$ 10.7 billion, with an average term of 3.7 years and an average cost of CDI + 1.76% p.a.

In December 2024, the cash, cash equivalents and marketable securities position totaled R$ 1.9 billion, accounting for 2.0x loans maturing by the end of 2025, in the amount of R$ 939 million.



Investments

(R$ million)	2023	2024	Δ
Total investment	**729**	**547**	**-25%**
% Gross income	*4.7%*	*3.3%*	*-1.4 p.p.*
Investment by category	**729**	**547**	**-25%**
Maintenance and expansion	419	364	-13%
Technology	310	182	-41%
Investment by BU	**729**	**547**	**-25%**
BU1	262	163	-38%
BU2	179	208	16%
Corporate	289	176	-39%

In 2024, investments totaled R$ 547 million, a 25% decrease compared to the R$ 729 million invested in 2023. As a result, the total investments in 2024 were 3% lower than the budget limit approved by the Board of Directors as published on March 27, and a reduction of 22% vs. 2023 and 56% vs. 2022.

The lower investments in 2024 reflect the Company's intention to prioritize expansion projects with a higher return in the short term, maintain existing assets and strengthen its technology services, which play a fundamental role in operations and in maintaining quality and excellence in the provision of medical, hospital, oncology and diagnostic services.

Corporate governance and management

Incentivized projects - 2024-2025 cycle

At the end of 2024, the decision-making matrix for the selection of incentivized projects to be supported by Dasa was reviewed, following the best practice criteria of B3's ISE and adopting health markers (WHO) as project selection criteria. As a result, we increased cover to socially vulnerable communities compared to the previous cycle, selecting 13 projects that will serve around 10,000 children, young people and adults in ongoing training programs. They are also expected to provide access to cultural events for around 700,000 people. All the projects are aligned with Dasa's priority SDGs (03, 10 and 13).

Capital increase

On November 25, 2024, Dasa's Board of Directors confirmed the capital subscriptions and the Company's capital increase, within the limit of the authorized capital, through the issuance of new common, book-entry, registered shares, without par value ("Shares"), approved by the Company's Board of Directors at a meeting held on September 9, 2024 ("Capital Increase"). The Capital Increase of 502,206,800 Shares was subscribed and paid up, of which 472,930,319 Shares were subscribed through the capitalization of an advance for future capital increase, as disclosed in the Material Fact dated May 15, 2024 and approved by the Board of Directors on the same date ("AFAC"), and 29,276,481 Shares subscribed by the Company's other shareholders, through the exercise of preemptive rights and subscription of surpluses and additional surpluses, representing a total of 83.68% of the Shares available for subscription. The Capital Increase was approved, with an issue of R$ 1,592,856,642.55 (higher than the minimum subscription of R$ 1,500,000,000.00), through the issue of 502,206,800 Shares, at an issue price of R$ 3.17171460565751 per Share, set under the terms of Article 170, paragraph 1, item III of Law 6404/76, with the cancellation of unsubscribed Shares. As a result of the ratification, the Company's share capital changes from R$ 18,032,489,013.94, divided into 752,799,844 common, registered, book-entry shares with no par value, to R$ 19,625,345,656.49, divided into 1,255,006,644 common, registered, book-entry shares with no par value.

Internal policies and regulations

On December 30, 2024, Dasa's Board of Directors approved the updating of the Company's Nomination Policy, Compensation Policy and Sustainability Policy, as well as the new Hiring Policy and the new Corporate Social Responsibility Policy, all of which were disclosed under the terms of the applicable regulations.

The first review of the Sustainability Policy was aimed at aligning it with the Company's current practices. A principled approach was adopted to the document, excluding strategic guidelines. The review of the text focused on adjustments to Dasa's policies and procedures, including Dasa's Social Responsibility Policy and Code of Ethics; as well as bringing it into line with international laws and principles.

The publication of the Corporate Social Responsibility Policy aims to establish guidelines for Dasa's actions in the areas of "Private Social Investment and Social Impact," including topics such as donations, sponsorships, volunteering, among others. A principled approach to the document was also adopted.

Association agreement between DASA and Amil

On February 4, 2025, DASA and Amil approved an amendment to the Association Agreement to, among other aspects, (i) change the amount of Ímpar's net debt at the close of the transaction from R$ 3.85 billion to R$ 3.5 billion, including net financial debt, the balance of derivative transactions, accounts payable for acquisitions and tax installment payment; and (ii) change the amount of net debt that will be contributed at the closing of the transaction, together with Amil's assets, from zero (0) reais to cash of R$ 350 million. As a result of this change, net debt, after the transaction closing, is expected to be R$ 3.15 billion.

On February 14, 2025, Impar issued three million (3,000,000) simple debentures, not convertible into shares, with real guarantee, unsecured, in a single series, of the second (2nd) issue, with a nominal unit value of one thousand reais (R$ 1,000.00), totaling, on the issue date, R$ 3,000,000,000.00. The amounts were received by Impar on February 26, 2025.

Part of the proceeds from this fundraising was used to early redeem the 18th issue of DASA debentures in the amount of R$ 1,000,000,000.00 on March 11, 2025.

On February 26, 2025, the spin-off of Ímpar's assets was approved merging the spun-off assets by DASA and its wholly-owned subsidiary, Dasa Real Estate Empreendimentos Imobiliários Ltda. This spin-off segregated Ímpar's assets located outside the scope of the Association Agreement.

On February 28, 2025, the capital of Ímpar was reduced in the amount of R$ 2,075,000,000.00.

Novo Mercado Free Float Waiver

On February 22, 2024, DASA informed the market of B3's response to its waiver request regarding the minimum percentage of free-float shares pursuant to article 10 of the B3 Novo Mercado regulations. As a result of the Company's capital increase in the fourth quarter of 2024 (Note 2.b), the deadline for recomposition of the free float, which was February 19, 2025, was automatically extended to May 25, 2026, under the terms of Article 11, item II of the Novo Mercado Regulations. If the free float percentage reaches a level higher than 14.11% (percentage after the capital increase) at any time during the above period, will not be allowed to be reduced until the minimum percentage established by the Novo Mercado Regulations is reached.

Changes to the Statutory Board

On March 6, 2025, Dasa's Board of Directors approved (i) the resignation submitted by Ms. Nelcina Conceição de Oliveira Tropardi as Director without Specific Designation of the Company and Vice President of the Legal, Compliance, ESG, Government Relations and Internal Audit areas; and (ii) the election of Mr. Fábio Sampaio de Lacerda to occupy the position of Director without Specific Designation and Vice President of People, Management and Culture in the Diagnostics Unit.

Acknowledgment

We would like to express our appreciation to everyone who contributed to another year of important achievements for the Company.

São Paulo, March 26, 2025.

The Management.

(A free translation of the original in Portuguese)

Diagnósticos da América S.A.

Balance sheet

December 31, 2024 and 2023

(In thousands of reais)

	Note	Parent Company		Consolidated	
		12/31/2024	12/31/2023	12/31/2024	12/31/2023
CURRENT ASSETS					
Cash and cash equivalents	5	461,263	521,440	1,742,762	1,585,194
Securities	6	88,898	79,561	152,567	103,815
Trade accounts receivable	7	1,233,231	1,000,860	4,950,821	3,976,643
Inventories	8	150,607	163,717	465,538	450,977
Recoverable taxes	9	262,792	349,264	510,735	602,040
Related parties	30d	1,973,394	1,259,559	-	-
Asset from discontinued operations	32	-	-	4,359	-
Other receivables		85,676	178,378	376,280	312,845
TOTAL CURRENT ASSETS		4,255,861	3,552,779	8,203,062	7,031,514
NON-CURRENT ASSETS					
LONG-TERM ASSETS					
Restricted financial investments	19	6,448	6,475	7,165	6,605
Trade accounts receivable	7	31,509	12,191	36,274	15,937
Recoverable taxes	9	41,902	62,104	42,281	62,104
Derivative financial instruments	29	-	-	-	7,165
Judicial deposits	20	61,252	59,653	132,144	118,160
Deferred taxes	27	1,085,055	936,030	1,491,859	1,286,050
Related parties	30b	479,764	236,120	-	-
Other receivables		140,771	103,840	262,481	467,604
NON-CURRENT RECEIVABLES		1,846,701	1,416,413	1,972,204	1,963,625
Investments	10	10,484,124	10,287,277	3,900	4,175
Property and equipment	11	955,154	1,085,016	3,876,275	4,004,874
Right of use	13	759,173	889,855	2,315,675	2,474,055
Intangible assets	12	3,044,561	3,235,564	10,087,355	10,734,957
TOTAL NON-CURRENT ASSETS		17,089,713	16,914,125	18,255,409	19,181,686
TOTAL ASSETS		21,345,574	20,466,904	26,458,471	26,213,200

	Note	Parent company		Consolidated	
		12/31/2024	12/31/2023	12/31/2024	12/31/2023
CURRENT LIABILITIES					
Suppliers	14	599,103	628,802	1,438,273	1,538,242
Loans and financing	15	-	4,743	2,609	122,966
Debentures	16	935,242	1,194,698	935,242	1,395,830
Income tax and social contribution payable		-	-	171,211	26,513
Social charges and labor obligations	17	311,076	230,081	765,183	613,597
Taxes payable	18	72,680	64,033	283,053	316,818
Payable - acquisition of subsidiaries	19	70,109	78,630	523,426	505,146
Dividends and interest on own capital	22e	-	155	34,237	44,320
Derivative financial instruments	29	1,141	885	1,141	885
Provision for unsecured liability in subsidiaries	10	158,383	71,609	-	-
Lease liabilities	13	220,123	182,195	343,384	378,598
Share-based payment	21	-	56,075	-	56,075
Liability from discontinued operation	32	-	-	-	784
Advance from customers		97,347	-	256,990	94,028
Other accounts payable and provisions		177,904	157,315	544,302	547,573
TOTAL CURRENT LIABILITIES		2,643,108	2,669,221	5,299,051	5,641,375
NON-CURRENT LIABILITIES					
Suppliers	14	44,569	46,738	44,574	46,743
Loans and financing	15	-	7,215	7,399	69,304
Debentures	16	9,451,759	9,063,337	9,451,759	9,063,337
Taxes payable	18	-	476	75,424	108,014
Payable - acquisition of subsidiaries	19	20,124	67,776	544,584	761,802
Derivative financial instruments	29	323,767	23,601	323,767	25,106
Provision for tax, social security, labor and civil	20	80,388	109,619	187,624	459,617
Lease liabilities	13	632,775	745,806	2,252,994	2,264,593
Share-based payment	21	-	16,962	-	16,962
Deferred taxes	27	14	-	21,547	13,198
Related parties		205,520	250,073	36,468	45,212
Other accounts payable and provisions		17,543	135,653	277,632	364,118
TOTAL NON-CURRENT LIABILITIES		10,776,459	10,467,256	13,223,772	13,238,006
TOTAL LIABILITIES		**13,419,567**	**13,136,477**	**18,522,823**	**18,879,381**
SHAREHOLDERS' EQUITY					
Share capital	22a	19,539,061	17,946,204	19,539,061	17,946,204
Capital reserves	22b	1,011,373	987,908	1,011,373	987,908
Treasury shares	22d	(79,136)	(81,258)	(79,136)	(81,258)
Equity valuation adjustment	22c	(9,666,522)	(9,842,648)	(9,666,522)	(9,842,648)
Accumulated deficit		(2,878,769)	(1,679,779)	(2,878,769)	(1,679,779)
TOTAL SHAREHOLDERS' EQUITY		7,926,007	7,330,427	7,926,007	7,330,427
Non-controlling interest in subsidiaries		-	-	9,641	3,392
TOTAL SHAREHOLDERS' EQUITY		7,926,007	7,330,427	7,935,648	7,333,819
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		21,345,574	20,466,904	26,458,471	26,213,200

See the accompanying notes to the individual parent company and consolidated financial statements.

(A free translation of the original in Portuguese)
Diagnósticos da América S.A.

Statement of income
Years ended December 31, 2024 and 2023
(In thousands of reais, unless otherwise indicated)

	Note	Parent Company		Consolidated	
		12/31/2024	12/31/2023	12/31/2024	12/31/2023
Net operating revenue	23	5,577,916	5,214,821	15,322,079	14,252,235
Cost of services rendered	24	(3,692,489)	(3,537,417)	(11,128,831)	(10,365,230)
Gross revenue		**1,885,427**	**1,677,404**	**4,193,248**	**3,887,005**
General and administrative expenses	24	(1,455,940)	(1,350,392)	(3,186,724)	(2,975,303)
Other income (expenses), net		23,259	(4,110)	87,469	1,621
Equity in results of subsidiaries	10.2	(542,437)	(837,568)	-	-
Profit before financial result and income tax and social contribution		**(89,691)**	**(514,666)**	**1,093,993**	**913,323**
Financial income	25	203,606	236,558	254,236	296,819
Financial expenses	25	(1,461,246)	(892,042)	(2,415,586)	(2,206,096)
Financial expenses, net		**(1,257,640)**	**(655,484)**	**(2,161,350)**	**(1,909,277)**
Loss before income tax and social contribution		**(1,347,331)**	**(1,170,150)**	**(1,067,357)**	**(995,954)**
Current income tax and social contribution	27	(3,530)	-	(342,592)	(131,888)
Income tax and social contribution - deferred	27	151,871	4,134	214,020	(1,928)
Loss from continued operations in the year		**(1,198,990)**	**(1,166,016)**	**(1,195,929)**	**(1,129,770)**
Profit (loss) from discontinued operations	32	-	-	1,978	(28,229)
Loss for the year		**(1,198,990)**	**(1,166,016)**	**(1,193,951)**	**(1,157,999)**
Profit (loss) attributable to:					
Controlling shareholders		-	-	(1,198,990)	(1,166,016)
Non-controlling interest in subsidiaries		-	-	5,039	8,017
Loss for the year		**(1,198,990)**	**(1,166,016)**	**(1,193,951)**	**(1,157,999)**
Total loss per common share					
Basic (in Reais)	26	(0.95955)	(1.56083)		
Diluted (in Reais)	26	(0.93064)	(1.48372)		
Number of shares - basic (in thousands)	26	1,249,533	747,048		
Number of shares - diluted (in thousands)	26	1,288,356	785,871		

See the accompanying notes to the individual parent company and consolidated financial statements.

Statements of comprehensive income
Years ended December 31, 2024 and 2023
(In thousands of reais)

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Loss for the year	(1,198,990)	(1,166,016)	(1,193,951)	(1,157,999)
Effect on translation of financial statements of foreign subsidiaries	36,172	(93,637)	36,172	(93,637)
Effect of the adoption of CPC 42 / IAS 29 - Financial Reporting in Hyperinflationary Economies	174,633	(53,743)	174,633	(53,743)
Comprehensive income for the year	**(988,185)**	**(1,313,396)**	**(983,146)**	**(1,305,379)**

	Consolidated 12/31/2024	Consolidated 12/31/2023
Comprehensive income attributable to:		
Controlling shareholders	(988,185)	(1,313,396)
Subsidiaries' non-controlling shareholders	5,039	8,017
Comprehensive income for the year	**(983,146)**	**(1,305,379)**

See the accompanying notes to the individual parent company and consolidated financial statements.

(A free translation of the original in Portuguese)

Diagnósticos da América S.A.

Statements of changes in shareholders' equity
Years ended December 31, 2024 and 2023
(In thousands of reais)

		Share capital		Capital reserve								
	Note	Share capital	Share issuance expenses	Goodwill reserve	Transactions with share-based payments	Treasury shares	Accumulated deficit	Equity valuation adjustment	Other comprehensive income	Total parent company	Non-controlling shareholders	Total consolidated
Balance at December 31, 2022		**16,359,199**	**(56,961)**	**432,772**	**505,574**	**(39,202)**	**(448,290)**	**(9,473,502)**	**(200,969)**	**7,078,622**	**10,777**	**7,089,399**
Capital increase	22a	1,673,290		-	-	-	-	-	-	1,673,290	-	1,673,290
Share issuance expenses	22a	-	(29,324)	-	-	-	-	-	-	(29,324)	-	(29,324)
Treasury shares acquired	22	-	-	-	-	(107,530)	-	-	-	(107,530)	-	(107,530)
Transactions among shareholders	22	-	-	-	-	65,473	(65,473)	(20,797)	-	(20,797)	(15,402)	(36,199)
Loss for the year		-	-	-	-	-	(1,166,016)	-	-	(1,166,016)	8,017	(1,157,999)
Other comprehensive income		-	-	-	-	-	-	-	(147,380)	(147,380)	-	(147,380)
Stock option plan	21	-	-	-	49,562	-	-	-	-	49,562	-	49,562
Balance at December 31, 2023		**18,032,489**	**(86,285)**	**432,772**	**555,136**	**(81,258)**	**(1,679,779)**	**(9,494,299)**	**(348,349)**	**7,330,427**	**3,392**	**7,333,819**
Capital increase	2b|22a	1,592,857	-	-	-	-	-	-	-	1,592,857	-	1,592,857
Transactions among shareholders	22	-	-	-	-	2,122	-	(34,679)	-	(32,557)	1,210	(31,347)
Loss for the year		-	-	-	-	-	(1,198,990)	-	-	(1,198,990)	5,039	(1,193,951)
Other comprehensive income		-	-	-	-	-	-	-	210,805	210,805	-	210,805
Stock option plan	21	-	-	-	23,465	-	-	-	-	23,465	-	23,465
Balance at December 31, 2024		**19,625,346**	**(86,285)**	**432,772**	**578,601**	**(79,136)**	**(2,878,769)**	**(9,528,978)**	**(137,544)**	**7,926,007**	**9,641**	**7,935,648**

See the accompanying notes to the individual parent company and consolidated financial statements.

(A free translation of the original in Portuguese)
Diagnósticos da América S.A.

Statements of cash flow
Years ended December 31, 2024 and 2023
(In thousands of reais)

	Note	Parent Company 12/31/2024	Parent Company 12/31/2023	Consolidated 12/31/2024	Consolidated 12/31/2023
Cash flows from operating activities					
Loss before income tax and social contribution		**(1,347,331)**	**(1,170,150)**	**(1,067,357)**	**(995,954)**
Items that do not affect cash and cash equivalents:					
Depreciation and amortization	11|12|13	773,545	801,784	1,366,818	1,296,305
Provisions for tax, social security, labor and civil	20	78,321	80,844	129,116	97,941
Write-off of goodwill from discontinued operation	12.g	-	37,938	-	37,938
Accrued interest and exchange-rate effects from loans and financing, property and equipment, intangible assets and payable - acquisition of subsidiaries		1,344,083	1,507,784	1,570,936	1,751,783
Unrealized results from derivative financial instruments		300,422	24,486	306,082	36,215
Loss (gain) on disposal of subsidiary, property and equipment, intangible assets and right of use	11|12|13	60,303	(1,160)	203,109	16,820
Update of share-based payment	21	(47,450)	66,401	(47,450)	66,590
Equity in results of subsidiaries	10.2	542,437	837,568	-	-
Provisions for expected losses from doubtful accounts	7	3,233	9,342	40,173	1,189
Provision (reversal) of disallowances	7	13,472	(21,088)	159,900	148,224
Accrued interest and exchange-rate effects on financial investment	6	(9,337)	(115,602)	(5,699)	(113,382)
Provision (reversal) for inventory losses	8	2,980	-	14,089	(519)
Accrued interest on lease	13	103,309	88,898	305,688	217,993
(Increase) decrease in assets					
Accounts receivable	7	(262,584)	(69,660)	(1,199,403)	(830,176)
Inventories	8	10,826	9,353	(28,650)	26,138
Other current assets		(560,658)	(862,039)	(33,869)	(12,845)
Other non-current assets		(196,823)	(68,463)	210,677	(82,094)
Increase (decrease) in liabilities					
Suppliers	14	(40,576)	(131,353)	(108,200)	(40,397)
Accounts payable and provisions		68,100	(102,768)	(10,315)	(511,198)
Payment of stock option plan	21	-	(828)	-	(828)
Discontinued operations		-	-	(3,165)	-
		836,272	**921,287**	**1,802,480**	**1,109,743**
Interest paid on loans, financing and debentures	15|16	(1,212,466)	(1,595,444)	(1,243,222)	(1,680,776)
Payment of lease interest	13	(103,309)	(88,898)	(305,688)	(217,993)
Income tax and social contribution paid		-	(1,644)	(225,624)	(174,598)
Cash flow generated (used) by operating activities		**(479,503)**	**(764,699)**	**27,946**	**(963,624)**
Cash flows from investing activities					
Acquisition of property and equipment	11	(272,206)	(175,032)	(474,845)	(474,609)
Acquisition of intangible assets	12	(44,751)	(194,407)	(63,654)	(336,640)
Advance for future capital increase and capital increase in subsidiaries	10	(905,340)	(1,138,029)	-	-
Dividends and interest on own capital received from subsidiaries		83,593	33,304	-	-
Amount received for sale of subsidiaries	2.h	195,000	-	195,000	-
Acquisition of subsidiary, less cash received	3.2.b.1	-	-	528	(7,636)
Proceeds on disposal of property and equipment and intangible assets	11|12	43,605	959	44,034	1,147
Acquisition of subsidiaries' non-controlling shareholders	2.e	(31,409)	-	(31,409)	-
Financial investments	6	-	(6,136,340)	(90,365)	(5,737,492)
Redemption of financial investments	6	-	7,511,527	47,118	7,534,188
Cash from merger of subsidiary	10	19,172	87,296	-	-
Cash flow generated (used) by investing activities		**(912,336)**	**(10,722)**	**(373,593)**	**978,958**
Cash flow from financing activities					
New loans, financing and debentures	15|16	1,710,000	3,300,000	1,710,000	3,300,000
Payment of loans, financing and debentures	15|16	(1,699,980)	(3,522,992)	(2,074,626)	(3,971,446)
Dividends and interest on own capital paid		-	-	(10,083)	-
Share issuance expenses	22	-	(29,325)	-	(29,325)
Repurchase of shares	22	-	(107,526)	-	(107,526)
Capital increase	22	1,592,857	1,673,291	1,592,857	1,673,291
Payments for acquisition of subsidiaries	19	(74,002)	(83,851)	(353,734)	(238,187)
Payment of principal - Lease	13	(197,213)	(170,592)	(361,199)	(341,939)
Cash flow generated by financing activities		**1,331,662**	**1,059,005**	**503,215**	**284,868**
Increase (decrease) in cash and cash equivalents		**(60,177)**	**283,584**	**157,568**	**300,202**
Balances of cash and cash equivalents:					
At the beginning of the year	5	521,440	237,856	1,585,194	1,284,992
At the end of the year	5	461,263	521,440	1,742,762	1,585,194
		(60,177)	**283,584**	**157,568**	**300,202**

See the accompanying notes to the individual parent company and consolidated financial statements.

(A free translation of the original in Portuguese)
Diagnósticos da América S.A.

Statements of value added
Years ended December 31, 2024 and 2023
(In thousands of reais)

	Note	Parent Company		Consolidated	
		12/31/2024	12/31/2023	12/31/2024	12/31/2023
Income					
Sale of goods, products and services	23	6,112,324	5,630,149	16,799,610	15,557,256
Other income		23,260	13,344	87,469	145,447
(Expected losses) / recovery of doubtful accounts	7	(16,705)	11,746	(200,073)	(149,412)
Inputs acquired from third parties					
Cost of products, goods sold, and services provided		(2,352,210)	(2,410,823)	(7,203,580)	(7,388,136)
Materials, energy, outsourced services and other		(609,980)	(360,462)	(2,033,449)	(1,328,586)
Gross value added		**3,156,689**	**2,883,954**	**7,449,977**	**6,836,569**
Depreciation and amortization	11|12|13	(773,545)	(801,784)	(1,366,818)	(1,296,305)
Net value added generated		**2,383,144**	**2,082,170**	**6,083,159**	**5,540,264**
Equity in results of subsidiaries	10.2	(542,437)	(837,568)	-	-
Financial income	25	203,606	236,558	254,236	296,819
Total value added payable		**2,044,313**	**1,481,160**	**6.337.395**	**5,837,083**
Distribution of value added		**2,044,313**	**1,481,160**	**6.337.395**	**5,837,083**
Personnel		**1,645,424**	**1,564,107**	**4,281,088**	**3,970,034**
Salaries		1,310,031	1,239,035	3,572,138	3,241,348
Contribution to the Severance Indemnity Fund (FGTS)		87,263	83,719	206,436	206,154
Benefits		248,130	241,353	502,514	522,532
Taxes, rates and contributions		**629,880**	**343,116**	**1,424,827**	**1,091,324**
Federal		450,913	205,700	1,009,406	714,907
State		4,897	89	8,873	149
Municipal		174,070	137,327	406,548	376,268
Third-party capital remuneration		**967,999**	**739,953**	**1,825,431**	**1,933,724**
Interest on funding, financing and leases		967,999	739,953	1,825,431	1,933,724
Remuneration of own capital		**(1,198,990)**	**(1,166,016)**	**(1,193,951)**	**(1,157,999)**
Loss for the year		(1,198,990)	(1,166,016)	(1,198,990)	(1,166,016)
Profit attributable to non-controlling shareholders of subsidiaries		-	-	5,039	8,017

See the accompanying notes to the individual parent company and consolidated financial statements.

1 Operations

Diagnósticos da América S.A. ("DASA", "Parent Company" or "Company") and, jointly with its subsidiaries ("DASA Group" or "Consolidated") is headquartered at Avenida Juruá, nº. 434, Alphaville, CEP 06455-010, city of Barueri, State of São Paulo, Brazil. DASA is a publicly-held corporation, registered with the Brazilian Securities Commission (CVM) on November 5, 2004, and trades its shares on the Novo Mercado of B3 S.A. - Brasil, Bolsa, Balcão ("B3") stock market, being the highest level of corporate governance segment in the Brazilian capital market, under the ticker DASA3.

The Company, through its own operations as well as through its subsidiaries, is engaged in the provision of the services to and for: (i) outpatient physicians; (ii) diagnostic support assistants for private patients or covered companies; (iii) hospitals, medical centers and outpatients; (iv) delivering care services, remote monitoring, population health management, home medical and paramedical services and outpatient medical activities for medical consultations; (v) development and licensing of computer programs; (vi) development and licensing of predictive models using information technology and data science; and (vii) brokerage fee.

2 Main events in 2024

(a) Joint venture agreement between DASA and Amil Assistência Médica Internacional S.A. ("Amil") ("Joint venture Agreement")

On June 14, 2024, DASA signed an Joint Venture Agreement with Amil, whereby Amil will contribute hospital and oncology assets to Ímpar Serviços Hospitalares S.A. ("Ímpar"), DASA's hospital and oncology company; with Ímpar becoming a joint venture, with equal equity interests of 50% of the voting capital between Amil and DASA, and governance model designed to maintain balanced rights, with three representatives of each partner and three independent members on the board and decisions mostly taken by a simple majority on the board. Amil will contribute to Ímpar certain hospitals and oncology clinics of the Rede Americas through a capital increase. In turn, Ímpar will remain all its operations, except for the hospitals and oncology units located in the Northeast region (Hospital São Domingos, Hospital da Bahia, and AMO), which will be apart from the transaction' perimeter.

As a result of the joint control between DASA and Amil in Ímpar and the applicability of CPC 18 (R2)/IAS 28 - Investments in Associates and Joint Ventures and CPC 19 (R2)/IFRS 11 - Joint Arrangements, following the closing the transaction, DASA will no longer consolidate Ímpar's financial statements, recognizing both the investment and its results under the equity accounting method.

The transaction is subject to certain customary conditions precedent, including consent from third parties. On the date of authorization and issuance of these financial statements, these conditions are still in progress for completion. On December 24, 2024, the Administrative Council for Economic Defense (CADE) approved the transaction without restrictions, and a period of 15 days has elapsed for any objections from third parties or CADE Court response. For further information on the progress of the transaction, see Note 34 – Subsequent events.

Further information regarding the Joint venture Agreement, is detailed in the Material Fact notice - "Association Agreement in Hospitals" and Notice to the Market - "DASA Presentation", disclosed by the Company on June 14, 2024, as well as Material Fact notice disclosed on February 04, 2025 and Notices to the Market on December 26, 2024 and January 14, 2025, all available on the DASA Investor Relations ("IR") website of (www.dasa3.com.br).

(b) Advance for Future Capital Increase from controlling shareholders

On May 15, 2024, the Board of Directors approved the execution of a Private Agreement for Capital Increase between the Company and its controlling shareholders, by which the controlling shareholders commits to contribute R$ 1,500,000 to the Company. The advance for future capital (“AFAC”) increase seeks to provide the Company with resources to meet its operational and financial obligations and strengthen the Company’s working capital. The proceeds are intended solely and exclusively, irrevocably and unretractable, for the future capital increase of DASA. The advances do not bear interest, and, upon capitalization, the controlling shareholders will receive new registered, book-entry common shares with no par value, issued by the Company. The amount of R$ 1,500,000 was received by the Company in the second quarter of 2024.

Accordingly, under the Joint Venture Agreement, disclosed in Note 2.a, the period of 60 trading sessions begins on June 17, 2024 until September 6, 2024 for the calculation of the issue price of the shares as per the Material Fact notice disclosed on May 15, 2024. The issue price per common share is R$ 3.17171460565751 considering the volume-weighted average price (VWAP) of the 60 trading session prices.

On September 9, 2024, the Board of Directors approved a minimum subscription of R$ 1,500,000 and a maximum of R$ 1,903,451, through the minimum issuance of 472,930,318 and a maximum of 600,133,262 new common shares of the Company.

In the 4th quarter of 2024, DASA received R$ 92,857, corresponding to 29,276,481 common shares, as an exercise of subscription rights from non-controlling shareholders. On November 25, 2024, DASA’s Board of Directors approved the capital increase of R$ 1,592,857 through the issue of 502,206,800 shares, with the cancellation of unsubscribed shares. As a result, the Company’s share capital increased to R$ 19,625,346, represented by 1,255,006,644 registered common book-entry shares with no par value (Note 22.a).

(c) Issue of Debentures (21st Issue - Certificates of Real Estate Receivables (“CRIs”)):

On January 5, 2024, the Board of Directors approved the placement of the Company's 21st issue of simple, unsecured debentures, not convertible into shares, in up to five series, totaling up to R$ 2,137,500. This may be reduced if there is no exercise or partial exercise of the option for an additional lot of real estate receivables certificates issued by Vert Companhia Securitizadora - CRI, meeting a minimum of R$ 1,710,000, underwritten exclusively by the debenture holder as backing for the CRI. The net funds obtained and raised by the Company are to be applied by the Company, directly or through its subsidiaries, to pay expenses and costs not yet incurred by the Company or its subsidiaries, directly related to the payment of rents for certain properties and/or real estate projects described within the scope of the offer, as per the schedule for the use of the funds described in the operation. The operation was completed on January 31, 2024, upon placing a R$ 1,700,000 debentures, bearing interest at the Interbank Deposit Certificate (“CDI”) rate +2.12% p.a. with the last series maturing on January 15, 2034.

(d) Discontinuing of foreign operations

The DASA Group is in the process of reviewing its business portfolio, seeking to improve the synergies of its operations. Management focuses on efficiency of its main business units to reduce leverage and promote returns.

Thus, on November 6, 2023, Company decided to close the operations of the subsidiaries Optiren S.A. ("Optiren") and Nobeloy S.A. ("Nobeloy"), Uruguayan operations. In January 2024, the Company also decided to close the operations of Genia S.A. ("Genia Argentina"), Genia Colômbia SAS ("Genia Colombia"), and Genia Chile SPA ("Genia Chile"). The liquidation of Genia Colombia was completed in the fourth quarter of 2024. The final closure of these operations is expected to take place by 2025.

On December 31, 2024, the Company maintains these businesses classified as discontinued operations, since it has not completed all the conditions precedent required for closure. The information on the balance sheet and statement of income from discontinued operations is presented in Note 32.

(e) Exercise of the call option of Instituto de Hematologia de S.J.R Preto Ltda ("Hemat")

On December 18, 2020, DASA and Hemat's shareholders signed the Shareholders' Agreement, to regulate the rights and obligations of the parties, including Hemat's management model, in which DASA currently holds 80% of the shares.

On February 6, 2024, the parties entered into an out-of-court settlement agreement defining the sale and transfer of all the shares (20%) held by Hemat's minority shareholders to DASA for R$ 3.6 million, DASA became the sole shareholder of Hemat.

(f) Purchase of the remaining shares of DB Genética Serviços Laboratoriais Ltda. ("DB Genera")

On February 1, 2019, DASA and the shareholders of DB Genera entered into a Share Purchase and Sale Agreement and Other Covenants, whereby DASA acquired 75% of DB Genera´s shares.

On April 3, 2024, the shareholders entered into an out-of-court settlement agreement defining the sale and transfer of all the shares (25%) to DASA by the amount of R$ 27.8 million, DASA became the sole shareholder of DB Genera.

(g) Mergers

In its continuing efforts to rationalize its corporate structure and reduction of costs, the Company merged with Laboratório de Pesquisas Clínicas e Bromatológicas Ltda. ("Laboratório Biomédico") on April 30, 2024, and on September 2, 2024, of Sall Participações S.A. ("Sall") and Laboratório Deliberato de Análises Clínicas Ltda. ("Laboratório Deliberato").

The Company highlights (a) inapplicability of Article 264 of Law 6404/76 since there was no change in ownership in the mergers, and (b) there was no right of withdrawal for the Company' shareholders due to the mergers.

(h) Sale of Dasa Empresas

On October 9, 2024, DASA signed an agreement for the sale of its insurance brokerage and consulting business, represented by 12 subsidiaries, two of which are direct subsidiaries, Allbrokers Brasil Corretora de Seguros Ltda. and Gesto Saúde Sistemas Informatizados, Consultoria Médica e Corretora de Seguros Ltda., and their respective subsidiaries, collectively referred to as "Dasa Empresas", for R$ 255 million, of which R$ 195 million due at closing, R$ 10 million in 12 months after the closing date (subject to the usual cash/debt adjustment) and R$ 50 million as an earn-out over five years. On December 20, 2024, all regulatory approvals were received, and the transaction was completed.

(i) Novo Mercado Free Float Waiver

On February 22, 2024, DASA informed the market of B3's response to its waiver request regarding the minimum free-float percentage for shares pursuant to article 10 of the B3 Novo Mercado regulations. As a result of the Company's capital increase in the fourth quarter of 2024 (Note 2.b), the deadline for recomposition of the free float, which was February 19, 2025, was automatically extended to May 25, 2026, under the terms of Article 11, item II of the Novo Mercado Regulations. If the free float percentage reaches a level higher than 14.11% (percentage after the capital increase) at any time during the above period, will not be allowed to be reduced until the minimum percentage established by the Novo Mercado Regulations is reached.

3 Presentation of the financial statements

The issue of these individual parent company and consolidated financial statements was authorized by the Board of Directors in a meeting held on March 26, 2025.

3.1 Basis of preparation and presentation

The individual parent company and consolidated financial statements were prepared under accounting practices adopted in Brazil, including the pronouncements issued by Accounting Pronouncement Committee (CPC) and International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB). Disclosures are limited to all matters of significance to the financial statements, which are consistent with the information utilized by management in the performance of its duties.

The preparation of financial statements requires the use of certain estimates and assumptions. The Company's management has used its judgment in applying accounting policies and for reporting its assets, liabilities, income and expenses. Estimates and judgments are continually assessed and are based on prior experience and other factors, plus expected future events considered reasonable in the circumstances and actual results may be different from these estimates. The effects of reviews of estimates are recognized prospectively in the financial statements. The areas requiring the highest level of judgment and of greater complexity, and the areas where assumptions and estimates are significant and critical to the financial statements, are: i) discount rates and growth projections in determining the fair value of business combinations (Note 3.2.b); ii) provision for expected losses from doubtful accounts on accounts receivable (Note 7) and variable consideration in the recognition of income (Notes 7 and 23); iii) useful life of the property and equipment (Note 11); iv) useful life of intangible assets and impairment test of intangible assets and goodwill for expected future profitability ("goodwill") (Note 12); v) discount rates and projected inflation for lease agreements (Note 13); vi) recognition and measurement of provisions for tax, social security, labor and civil claims (Note 20); and vii) recognition of deferred tax assets (Note 27).

The individual parent company and consolidated financial statements were prepared on the historical cost basis, except for the following items measured at fair value: i) payable - acquisition of subsidiaries and non-controlling shareholder options of subsidiaries (Note 19); ii) share-based payment plan (Note 21); iii) financial instruments measured at fair value through profit or loss (Note 29).

The book values of the non-financial assets are reviewed at each balance sheet date for indicators of impairment. An impairment loss is recognized when the book value of the asset exceeds its recoverable value which reflects the higher value between the fair value of the asset minus costs to sell and its value in use. If such indication exists, the asset's recoverable amount is estimated and recognized.

The accounting policies applied in the preparation of these financial statements are presented in the notes to the financial statements.

3.2 Consolidation

a) Principles of consolidation

The consolidated financial statements include the financial information of the Company and its subsidiaries. An entity is controlled when the DASA Group: (i) exercises control, directly or indirectly; (ii) is exposed, or has a right over the variable returns arising from its involvement with the entity and (iii) has the ability to affect those returns by its power over the entity. The subsidiaries are consolidated as of the date control is transferred to the DASA Group, and stop being consolidated when control no longer exists.

When the DASA Group loses control of a subsidiary, the gain or loss on disposal is recognized in the statement of income for the year, calculated as the difference between the fair value of the consideration received and the write-off of the book value of the investment and the goodwill previously recognized on its acquisition.

In the preparation of the consolidated financial statements, the interests of one subsidiary in another, the outstanding balances of assets and liabilities, income, costs and expenses, as well as the effects arising from intercompany transactions, were eliminated. The non-controlling interest of subsidiaries is presented in a specific caption of the consolidated shareholders' equity and statement of income.

For acquisitions of non-controlling interest of subsidiaries, the difference between any considerations paid and the acquired portion of the book value of the subsidiary is directly recorded in shareholders' equity under "Equity valuation adjustments."

Information on direct subsidiaries is presented in Note 10.3.

In the parent company's individual financial statements, the results of its subsidiaries are recognized under the equity method and the amount of the respective investment is presented in non-current assets. If the subsidiary's shareholders' equity is negative, the amount is presented under current liabilities.

(In thousands of reais, unless otherwise indicated)

b) Business combination

Pursuant to CPC 15/IFRS 3 – Business Combinations, when the DASA Group obtains control of a company, the identifiable assets acquired and the liabilities assumed are measured on the acquisition date at their fair values, including contingent liabilities. Goodwill is determined on the acquisition date as the excess of the consideration transferred to obtain control (including contingent consideration payable), the non-controlling interest in the acquiree, if applicable, and the fair value of the identifiable assets acquired, and the liabilities assumed. Goodwill is an intangible asset with an indefinite useful life and should not be amortized. Goodwill is tested annually for impairment or when there are indications of losses in the book value. If a bargain purchase is determined, a gain is recognized in the statement of income on the acquisition date. Acquisition-related costs are recognized in the statement of income when incurred, except for costs related to the issue of debt and equity securities.

Contingent consideration payable is measured at fair value on the acquisition date and remeasured at fair value in each reporting period, with changes recognized the statement of income. If contingent consideration payable is an equity instrument, should not be remeasured and the settlement is recorded in shareholders' equity.

The Company and its subsidiaries had no business combinations in 2024. The following business combination was carried out in 2023:

b.1) Acquisition of Con – Oncologia, Hematologia, Centro de Infusão Ltda. ("Con")

On September 12, 2023, all the quotas Con were acquired by subsidiary Ímpar. Con has operates: oncology, hematology and infusion center in four units, two in the city of Rio de Janeiro, one in the municipality of São Gonçalo and the main unit in Niterói.

Impar's purchase consideration comprised the assumption to pay R$ 7,649, of which R$ 10,500 was deducted from the debt of R$ 2,851. At closing, R$ 3,432 was paid, while the remaining amount of R$ 4,217 will be settled in three annual installments, bearing CDI interest and a price adjustment due to net debt. The first installment due in September 2024 was reduced by R$ 528 by the net debt adjustment and, consequently, the total amount of the transaction was adjusted from R$ 7,649 to R$ 7,121.

Impar engaged an independent appraiser to allocate the price paid and valuate the assets acquired and liabilities assumed. No intangible assets were identified in this transaction. The final goodwill amounted R$ 6,964 and will only be deductible for tax purposes if the acquired company is merged in accordance with the applicable regulations.

The chart below summarizes the consideration paid to sellers and amounts of assets acquired and liabilities assumed on the dates of acquisition:

	Provisional amounts on 12/31/2023	**Final values calculated in 2024**
Current assets	4,805	4,805
Non-current assets	678	452
Liabilities	5,100	5,100
Total assets, net	**383**	**157**
Goodwill	7,266	6,964
Amount paid by the acquirer	**7,649**	**7,121**

3.3 Functional presentation currency and foreign currency translation

The Company's functional currency is the Brazilian Real/ Reais (R$). These financial statements are presented in thousands of Reais, unless otherwise indicated.

Transactions in foreign currency are translated into the Brazilian Reais at the exchange rates on the dates of the transactions. Monetary assets and liabilities are translated at the balance sheet exchange rate and the difference between these exchange rates is recognized in the Financial income (expense).

The financial statements of subsidiaries abroad are translated into Reais as follows: (i) assets and liabilities are translated into Reais at the exchange rate on the base date of the financial statements; (ii) income and expenses are translated at the average exchange rates; (iii) the amounts arising from the use of these different rates are recognized in shareholders' equity in other comprehensive income in the accumulated translation adjustments account and will be recognized in profit or loss when these subsidiaries are sold.

For subsidiaries based in Argentina (functional currency: Argentine Peso), CPC 42/IAS 29 – Accounting in Hyperinflationary Economies was applied, considering that annual inflation in 2024 was 117.8% (211.4% in 2023) according to the Consumer Price Index. Non-monetary items recorded at historical cost (such as property and equipment, intangible assets, inventories) and shareholders' equity, as well as the profit or loss for the year, are restated by the index between the initial date of recognition and the base date of the financial statements, so that the balance sheet of these subsidiaries is recorded at current value. The translation of balances from the Argentine Peso to the Real was made at the exchange rate on the base date of the financial statements, for both asset and income items.

3.4 Statement of Value Added ("DVA")

The presentation of the individual parent company and consolidated statement of value added is required by Brazilian corporate law and the accounting practices adopted in Brazil applicable to publicly-held companies. The Statement of Value Added was prepared in accordance with the CPC 09 - Statement of Value Added. The IFRS do not require the presentation of this statement and, therefore, is presented as supplementary information. Some amounts presented in the DVA on December 31, 2023, were reclassified for better comparability with the amounts presented in 2024.

4 New accounting standards and interpretations

Amendments to standards effective in 2024

The following standards, amendments to standards and interpretations to IFRS issued by the IASB are effective on January 1, 2024, but had no impact on the December 31, 2024 financial statements:

- Amendment to IAS 1 - Presentation of Financial Statements: classification of liabilities as non-current in the financial statements, in the case of liabilities containing covenants requiring the achievement of specific ratios.
- Amendment to IFRS 16 – Leases: clarifies the lease liability in a sale and leaseback transaction.
- Amendments to IAS 7 - Statement of Cash Flows and IFRS 7 - Financial Instruments: specific disclosure requirements on Supplier Finance Arrangements with the aim of enabling investors to assess the effects on an entity's liabilities, cash flows and exposure to liquidity risk.

(In thousands of reais, unless otherwise indicated)

Amendments to accounting standards that are not yet in force

The following standard has been issued by the IASB and will affect the DASA Group's financial statements:

- IFRS 18: Presentation and disclosure in the financial statements: establishes new requirements for the presentation of the statement of income for the year, classifying income and expenses as: operating, investment, financing, income taxes and discontinued operations. The Company must apply IFRS 18 for annual reporting periods beginning on January 1, 2027. The standard requires retrospective application with specific transition provisions. The effects of the standard are still being assessed by management.

The following standards have been issued by the IASB with no impact expected on the DASA Group's financial statements:

- Amendments to CPC 18 (R3) - Investments in Associates, Subsidiaries and Joint Ventures and ICPC 09 - Individual Financial Statements, separate statements, consolidated statements and application of the equity method;

- Amendments to CPC 02 (R2) – Effects of Changes in Exchange Rates and Translation of Financial Statements and CPC 37 (R1) – Initial Adoption of International Accounting Standards; and

- IFRS 19 – Subsidiaries without Public Accountability: Disclosure.

5 Cash and cash equivalents

Cash and cash equivalents include cash, bank deposits and other short-term, highly liquid investments, with original maturities of three months or less, readily convertible into cash with an insignificant risk of change in value. Cash equivalents are mainly funds invested in Brazil in private securities of financial institutions linked to the interest rate on Interbank Deposits ("DI") and repurchase and resale agreements.

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Cash and banks	28,583	116,423	164,233	438,908
Repurchase and resale agreements and CDB's (a)	432,680	405,017	1,578,529	1,146,286
	461,263	**521,440**	**1,742,762**	**1,585,194**

(a) Repurchase and resale commitments and CDBs (Bank deposit certificates) are remunerated, on average, at 98.4% of the CDI rate at December 31, 2024 (96.0% as of December 31, 2023). They have immediate liquidity and are not subject to restrictions or penalties.

(In thousands of reais, unless otherwise indicated)

6 Securities

The Company and its subsidiaries consider, as interest earning bank deposits, bank deposits and other short-, medium- and long-term liquid investments that do not meet all the criteria to be classified as cash equivalents under the terms of CPC 03 (R2)/IAS 7 – Statement of Cash Flows. Interest earning bank deposits are mainly invested funds: (i) in Brazil, in private bonds of financial institutions linked to the interest rate of Interbank Deposits ("DI"), repurchase agreements, financial bills, private securities and in short-term investment funds, of a portfolio composed of Brazilian federal government bonds and private bonds of financial institutions; (ii) abroad, in repurchase and resale agreements, government bonds, private securities and investment funds.

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Financial bill operations (a)	88,898	79,561	88,898	79,561
Repurchase and resale commitments abroad (b)	-	-	63,669	24,254
	88,898	**79,561**	**152,567**	**103,815**

(a) LF operations bear interest at 107.5% of the CDI rate, mature in 2025 and can be redeemed on the secondary market before maturity.
(b) Repurchase operations abroad are remunerated on average at 100% of the BADLAR interest rate (benchmark interest rate in Argentina).

7 Trade accounts receivable

Trade accounts receivable are for services rendered by the Company and its subsidiaries, recognized in the period in which the service is provided at the historical value of the transaction, less estimated losses from default and disallowance.

To analyze the recoverability of trade accounts receivable, the Company and its subsidiaries apply the calculation approach based on expected credit losses at each base date of the financial statements. The DASA Group uses a methodology for identifying recoverability risks of accounts receivable which considers the history of receipt and losses, recognizing a provision for disallowances upon partial receipts, and a provision for expected losses from doubtful accounts. Once a risk of deterioration of the balance has been identified, provisioning is made in accordance with the metrics defined in the study.

(In thousands of reais, unless otherwise indicated)

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Trade accounts receivable:				
Domestic (a)	1,230,495	995,971	5,453,559	4,332,855
Foreign	-	-	105,359	31,475
Related parties (Note 30.a)	101,354	67,484	-	-
	1,331,849	**1,063,455**	**5,558,918**	**4,364,330**
Expected losses from doubtful accounts	(32,965)	(29,732)	(191,580)	(151,407)
Expected losses from variable consideration (disallowances)	(34,144)	(20,672)	(380,243)	(220,343)
Expected losses on doubtful accounts and expected loss from variable consideration (disallowance)	**(67,109)**	**(50,404)**	**(571,823)**	**(371,750)**
Total trade accounts receivable, net	**1,264,740**	**1,013,051**	**4,987,095**	**3,992,580**
Current	1,233,231	1,000,860	4,950,821	3,976,643
Non-current	31,509	12,191	36,274	15,937

(a) On December 31, 2024, the Company and its subsidiaries had a credit card receivables prepayment operation with the respective acquirers, without co-obligation, in the amount of R$ 156,830 (R$ 122,177 in December 2023) and had a receivables prepayment operation with financial institutions, without co-obligation, in the amount of R$ 455,180 on December 31, 2023.

An analysis of the aging of trade receivables not yet due is as below:

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Yet to be invoiced	272,530	274,449	1,687,401	1,647,453
Not yet due	734,571	493,468	2,815,444	1,959,866
Overdue (days):				
≤90	141,071	109,749	506,358	327,993
91–120	25,055	22,832	66,692	53,937
121–180	34,019	31,206	87,808	72,100
181–360	42,161	76,645	166,068	161,467
>360	82,442	55,106	229,147	141,514
	1,331,849	**1,063,455**	**5,558,918**	**4,364,330**

Some amounts presented in the table above on December 31, 2023, were reclassified for better comparability with the amounts presented in 2024.

The changes in provisions were:

	Parent Company	Consolidated
Balance at December 31, 2022	**(20,390)**	**(150,219)**
Provision for estimated losses on doubtful accounts	(14,250)	(119,186)
Reversal/use	4,908	117,998
Balance at December 31, 2023	**(29,732)**	**(151,407)**
Provision for estimated losses on doubtful accounts	(14,112)	(73,311)
Reversal/use	10,879	33,138
Balance at December 31, 2024	**(32,965)**	**(191,580)**

(In thousands of reais, unless otherwise indicated)

Changes in expected losses from variable consideration (disallowances) are as follows:

	Parent Company	Consolidated
Balance at December 31, 2022	**(41,760)**	**(72,119)**
Provision for disallowance	(4,409)	(179,706)
Reversal/use of disallowances	25,497	31,482
Balance at December 31, 2023	**(20,672)**	**(220,343)**
Provision for disallowance	(23,797)	(160,829)
Reversal/use of disallowances	10,325	929
Balance at December 31, 2024	**(34,144)**	**(380,243)**

8 Inventories

Inventories refer mainly to clinical and hospital materials, medicines, vaccines and consumables for clinical analysis and diagnostic imaging tests and to patients care in hospitals. Inventories are shown at the lower of cost and net realizable value. Inventory costs are determined at the average weighted cost method.

Pharmaceutical, clinical and medical supplies have expiration dates assigned by the manufacturer. The expiration date is established based on the results of stability tests obtained on the primary packaging and secondary packaging. A provision for obsolescence is formed for materials without movement in the last 180 days and have an expiration date in the period analyzed. Overdue items are charged to the statement of income as incurred.

9 Recoverable taxes

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
PIS/COFINS (a) and CSLL (b) - withholding taxes on billings	35,340	37,728	53,085	52,810
IRPJ/CSLL (b) - recoverable	164,176	232,302	297,610	399,463
INSS (c) recoverable	92,146	135,294	120,530	143,632
ISS (d) recoverable	6,946	3,980	12,714	13,599
Other	6,086	2,064	69,077	54,640
	304,694	**411,368**	**553,016**	**664,144**
Current	262,792	349,264	510,735	602,040
Non-current	41,902	62,104	42,281	62,104

(a) PIS - Social Integration Program and COFINS - Tax for Social Security Financing.
(b) IRPJ - Corporate Income Tax and CSLL - Social contribution on Net Income.
(c) Social Security Charges - INSS.
(d) ISS - Services tax.

(In thousands of reais, unless otherwise indicated)

10 Investments

10.1 Parent Company balances

Parent Company	12/31/2024	12/31/2023
Investments in subsidiaries:		
Hospitals and oncology (BU1)	8,146,363	7,743,514
Diagnoses and care coordination ("BU2")	507,745	830,509
Diagnoses - International Operations (BU2 Internacional)	311,751	100,367
Investments in subsidiaries (Note 10.3)	8,965,859	8,674,390
Goodwill from acquired shares:		
Diagnoses and care coordination ("BU2")	1,026,644	1,087,977
Diagnoses - International Operations (BU2 Internacional)	25,644	25,613
Goodwill in the acquisition of interest	1,052,288	1,113,590
Intangible assets from acquisition of interest	462,780	496,309
Other investments	3,197	2,988
Total investments	**10,484,124**	**10,287,277**

Information by business segment (BU1, BU2 and BU2 Internacional) is presented in Note 28.

(In thousands of reais, unless otherwise indicated)

10.2 Interest in direct subsidiaries

Company	Segment	Year ended December 31, 2024				Year ended December 31, 2023			
		Interest in paid-up capital	Paid-up capital	Equity (Negative) proportional to interest held	Profit (loss) proportional to interest held	Interest in paid-up capital	Paid-up share capital	Equity (Negative) proportional to interest held	Profit (loss) proportional to interest held
Aliança Biotecnologia Ltda.	BU2	100.00%	1,462	216	(21)	100.00%	1,462	237	(57)
Allbrokers Brasil Corretora de Seguros Ltda. (f)	BU2	-	-	-	(13,194)	100.00%	236,054	226,526	(6,377)
Centro de Diagnóstico Boris Berenstein Ltda. (a)	BU2	99.99%	25,000	39,806	296	-	-	-	-
Centro de Tomografia por Computador Ltda. (b)	BU1	-	-	-	-	100.00%	150	15,081	6,849
Cientificalab Produtos Laboratoriais e Sistemas Ltda.	BU2	100.00%	125,177	204,645	46,898	100.00%	125,177	180,800	(16,915)
CPCLIN – Centro de Pesquisas Clínicas Ltda.	BU2	80.00%	1	5,150	4,025	80.00%	1	1,444	319
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	BU2	70.00%	1,080	2,660	1,066	70.00%	1,080	3,044	1,450
DASA Real Estate Empreendimentos Imobiliários Ltda.	BU2	100.00%	25,667	29,121	2,508	100.00%	25,667	29,223	2,747
DB Genética Serviços Laboratoriais Ltda.	BU2	100.00%	10	(64,205)	(4,705)	75.00%	10	(44,666)	(14,866)
Diagnóstico Maipú por Imágenes S.A.	BU2 International	100.00%	4,180	299,696	31,833	100.00%	1,784	84,784	(17,567)
Fernando Henriques Pinto Junior & Cia Ltda.	BU2	90.00%	51	(8,851)	(1,556)	90.00%	51	(7,295)	(1,931)
Genia S.A. (c)	BU2 International	100.00%	2,043	(8,634)	(2,254)	100.00%	1,075	(5,443)	(8,299)
Gesto Saúde Sistemas Informatizados, Consultoria Médica e Corretora de Seguros Ltda. (f)	BU2	-	-	-	(18,591)	100.00%	44,770	1,707	(12,286)
Ímpar Serviços Hospitalares S.A.	BU1	100.00%	7,991,700	8,146,363	(422,811)	100.00%	7,235,824	7,743,514	(549,091)
Instituto de Hematologia de S.J.R. Preto Ltda.	BU2	100.00%	8,680	(4,889)	(4,524)	80.00%	3,600	(4,352)	(5,303)
Itulab Laboratório de Análises Clín. de Itu Ltda.	BU2	100.00%	5,803	6,966	1,093	100.00%	5,803	7,131	1,414
Laboratório Bioclínico MS Ltda.	BU2	100.00%	5	(2,701)	(6,463)	100.00%	5	3,387	125
Laboratório Chromatox Ltda.	BU2	100.00%	3,366	9,603	3,431	100.00%	3,366	21,055	16,285
Laboratório Deliberato de Análises Clínicas Ltda. (d)	BU2	-	-	-	(685)	99.99%	6,800	13,143	5,906
Laboratório Médico Santa Luzia S.A. (e)	BU2	-	-	-	-	-	-	-	14,164
Laboratório Nobel S.A.	BU2	100.00%	15,863	8,723	(20,374)	100.00%	15,864	27,425	(20,571)
Laboratório de Pesquisas Clínicas e Bromatológicas Ltda. (d)	BU2	-	-	-	316	100.00%	11,058	8,414	583
Maringá Medicina Nuclear Ltda.	BU2	100.00%	15,600	19,626	(2,554)	100.00%	15,600	21,830	(6,292)
MO Holding S.A.	BU2	100.00%	16,022	146	(2)	100.00%	32,378	3,811	(30,902)
Mantris Gestão em Saúde Corporativa Ltda	BU2	100.00%	77,845	31,186	(19,179)	100.00%	77,845	35,736	15,736
Nobeloy S.A. (c)	BU2 International	100.00%	9,529	1,893	(96)	100.00%	12,404	7,997	(9,540)
Optiren S.A. (c)	BU2 International	100.00%	5,869	10,162	1,495	100.00%	4,588	7,586	(15,921)
Patologia Clínica Dr. Geraldo Lustosa Cabral Ltda.	BU2	100.00%	3,400	13,139	3,805	100.00%	3,400	12,158	5,078
Previlab Análises Clínicas Ltda.	BU2	99.65%	29,613	61,874	28,940	99.65%	29,613	45,981	13,782
Ruggeri & Piva Ltda.	BU2	100.00%	7,461	4,426	(960)	100.00%	7,461	5,386	(3,587)
SALL Participações S.A. (d)	BU2	-	-	-	(6,487)	100.00%	32,000	40,868	(2,257)
Salomão e Zoppi Serviços Médicos e Participações S.A.	BU2	100.00%	130,213	39,702	(31,781)	100.00%	130,213	71,483	(53,880)
Santa Celina Participações S.A.	BU2	100.00%	121,439	(68,905)	(59,053)	100.00%	121,439	(9,852)	(73,034)
Laboratório de Anatomia Patológica e Citopatologia São Camilo Ltda.	BU2	100.00%	3,372	3,279	(1,008)	100.00%	3,372	2,887	(2,072)
São Marcos – Saúde e Medicina Diagnóstica S.A.	BU2	100.00%	161,000	20,933	(37,848)	100.00%	62,600	47,298	(48,376)
Valeclin Laboratório de Análises Clínicas Ltda.	BU2	100.00%	12,839	6,346	(13,997)	100.00%	11,100	4,454	(22,882)
				8,807,476	**(542,437)**			**8,602,782**	**(837,568)**

(a) Upon the merger of Sall (Note 2.g), the company became a direct subsidiary of DASA.
(b) Following the corporate restructuring, the subsidiary is no longer classified as BU2 and is currently consolidated in BU1.
(c) Subsidiary classified as discontinued operations (Note 32).
(d) Subsidiary merged in 2024 (Note 2.g).
(e) Subsidiary merged in 2023.
(f) Subsidiary sold in 2024 (Note 2.h).

(In thousands of reais, unless otherwise indicated)

10.3 Investments in subsidiaries and provision for unsecured liabilities of subsidiaries

Investments in subsidiaries	Hospitals and oncology (BU1)	Diagnoses and care coordination ("BU2")	Diagnoses - International Operations (BU2 Internacional)	Total
Balance at December 31, 2023	**7,743,514**	**830,509**	**100,367**	**8,674,390**
Capital increase	755,876	1,739	-	757,615
Advance for future capital increase	81,741	64,141	2,582	148,464
Merger of subsidiaries	-	(20,779)	-	(20,779)
Transfer between investments and provision for unsecured liability in subsidiaries	-	2,899	-	2,899
Sale of interest in subsidiaries	-	(218,034)	-	(218,034)
Equity valuation adjustment (a)	(11,957)	(10,395)	175,570	153,218
Dividends and interest on own capital	-	(61,569)	-	(61,569)
Equity in results of subsidiaries	(422,811)	(80,766)	33,232	(470,345)
Balance at December 31, 2024	**8,146,363**	**507,745**	**311,751**	**8,965,859**

Provision for unsecured liabilities of subsidiaries	Hospitals and oncology (BU1)	Diagnoses and care coordination ("BU2")	Diagnoses - International Operations (BU2 Internacional)	Total
Balance at December 31, 2023	**-**	**(66,165)**	**(5,443)**	**(71,608)**
Capital increase	-	4,080	-	4,080
Advance for future capital increase	-	1,000	-	1,000
Acquisition of non-controlling interest	-	(15,927)	-	(15,927)
Transfer between investments and provision for unsecured liability in subsidiaries	-	(2,899)	-	(2,899)
Equity valuation adjustment (a)	-	-	(937)	(937)
Equity in results of subsidiaries	-	(69,838)	(2,254)	(72,092)
Balance at December 31, 2024	**-**	**(149,749)**	**(8,634)**	**(158,383)**
Net investments on December 31, 2024	**8,146,363**	**357,996**	**303,117**	**8,807,476**

(In thousands of reais, unless otherwise indicated)

Investments in subsidiaries	Hospitals and oncology (BU1)	Diagnoses and care coordination ("BU2")	Diagnoses - International Operations (BU2 Internacional)	Total
Balance at December 31, 2022	**7,341,849**	**987,403**	**207,691**	**8,536,943**
Capital increase	963,610	75,050	-	1,038,660
Advance for future capital increase	-	85,760	13,609	99,369
Merger of subsidiaries	-	(63,634)	-	(63,634)
Transfer between investments and provision for unsecured liability in subsidiaries	-	3,863	(2,856)	1,007
Change in shareholders' equity - acquisition of subsidiaries	-	(14,147)	-	(14,147)
Equity valuation adjustment (a)	(12,854)	4,568	(75,049)	(83,335)
Dividends and interest on own capital	-	(33,304)	-	(33,304)
Equity in results of subsidiaries	(549,091)	(215,050)	(43,028)	(807,169)
Balance at December 31, 2023	**7,743,514**	**830,509**	**100,367**	**8,674,390**

Provision for unsecured liabilities of subsidiaries	Hospitals and oncology (BU1)	Diagnoses and care coordination ("BU2")	Diagnoses - International Operations (BU2 Internacional)	Total
Balance at December 31, 2022	-	(35,164)	-	(35,164)
Transfer between investments and provision for unsecured liability in subsidiaries	-	(3,863)	2,856	(1,007)
Equity valuation adjustment (a)	-	(5,038)	-	(5,038)
Equity in results of subsidiaries	-	(22,100)	(8,299)	(30,399)
Balance at December 31, 2023	**-**	**(66,165)**	**(5,443)**	**(71,608)**
Net investments on December 31, 2023	**7,743,514**	**764,344**	**94,924**	**8,602,782**

(a) Asset valuation adjustments include hyperinflationary accounting adjustment and balance sheet conversion, among others.

Information by business segment (BU1, BU2 and BU2 Internacional) disclosed in Note 28.

11 Property and equipment

Property and equipment are measured at historical acquisition or construction cost, including expenses directly attributable to their acquisition, less accumulated depreciation and, if applicable, impairment losses. Subsequent costs are capitalized only when future economic benefits associated with the expenses occur, and the book value of replaced items or parts is written off. All other maintenance and repair costs are recognized in the statement of income for the year when incurred.

Depreciation is recognized under the straight-line method based on the estimated useful life of the assets, recognized in the statement of income under general and administrative expenses and costs of services rendered, matching the use of each asset. Depreciation methods, residual values and useful lives are reviewed annually and adjusted if necessary. The estimated useful lives are presented in the tables below and depreciation costs and expenses are disclosed in Note 24. Land is not depreciated.

Gains and losses on disposals are calculated as the difference between the sale price and the residual book value and recognized in the statement of income under other income and expenses, net.

(In thousands of reais, unless otherwise indicated)

Parent Company

	Useful life (years)	Balance at 12/31/2023	Addition (b)	Addition - merger (a)	Write-off	Transfers	Depreciation	Balance at 12/31/2024
Acquisition cost								
Properties	25	8,304	-	-	-	-	-	8,304
Leasehold improvements	10	1,027,358	-	934	(4,570)	24,071	-	1,047,793
Improvements to own properties	10	4,066	-	-	-	-	-	4,066
Machinery and equipment	10	1,535,494	-	371	(12,126)	80,859	-	1,604,598
Furniture and fixtures	10	135,211	-	104	(974)	2,130	-	136,471
Facilities	10	229,479	-	1,310	(1,022)	12,436	-	242,203
IT equipment	5	350,661	-	397	(2,863)	7,654	-	355,849
Vehicles	5	2,254	-	19	(19)	-	-	2,254
Land	-	180	-	-	-	-	-	180
Construction in progress (b)	-	90,534	274,921	-	(2,183)	(292,607)	-	70,665
Provision for recoverability	-	(983)	-	(4)	-	-	-	(987)
		3,382,558	**274,921**	**3,131**	**(23,757)**	**(165,457)**	**-**	**3,471,396**
Accumulated depreciation								
Properties		(1,702)	-	-	-	-	(319)	(2,021)
Leasehold improvements		(762,121)	-	(448)	3,676	-	(50,443)	(809,336)
Improvements to own properties		(4,042)	-	-	-	-	(19)	(4,061)
Machinery and equipment		(1,050,057)	-	(287)	9,298	-	(118,961)	(1,160,007)
Furniture and fixtures		(97,996)	-	-	625	-	(8,772)	(106,143)
Facilities		(130,391)	-	(13)	534	-	(17,013)	(146,883)
IT equipment		(248,979)	-	(384)	2,699	-	(38,873)	(285,537)
Vehicles		(2,254)	-	(19)	19	-	-	(2,254)
		(2,297,542)	**-**	**(1,151)**	**16,851**	**-**	**(234,400)**	**(2,516,242)**
		1,085,016	**274,921**	**1,980**	**(6,906)**	**(165,457)**	**(234,400)**	**955,154**

	Useful life (years)	Balance at 12/31/2022	Addition (b)	Addition - merger (a)	Write-off	Transfers	Depreciation	Balance at 12/31/2023
Acquisition cost								
Properties	25	8,304	-	-	-	-	-	8,304
Leasehold improvements	10	1,006,090	-	12,462	(3,933)	12,739	-	1,027,358
Improvements to own properties	10	4,066	-	-	-	-	-	4,066
Machinery and equipment	10	1,487,707	-	5,000	(5,214)	48,001	-	1,535,494
Furniture and fixtures	10	131,222	-	3,625	(501)	865	-	135,211
Facilities	10	223,607	-	1,573	(696)	4,995	-	229,479
IT equipment	5	345,716	-	2,808	(2,485)	4,622	-	350,661
Vehicles	5	2,164	-	574	(484)	-	-	2,254
Land	-	180	-	-	-	-	-	180
Construction in progress (b)	-	5,853	189,330	-	-	(104,649)	-	90,534
Provision for recoverability	-	(31,076)	-	-	30,093	-	-	(983)
		3,183,833	**189,330**	**26,042**	**16,780**	**(33,427)**	**-**	**3,382,558**
Accumulated depreciation								
Properties		(1,373)	-	-	-	-	(329)	(1,702)
Leasehold improvements		(690,785)	-	(7,718)	2,057	-	(65,675)	(762,121)
Improvements to own properties		(3,826)	-	-	-	-	(216)	(4,042)
Machinery and equipment		(913,874)	-	(3,069)	(3,292)	-	(129,822)	(1,050,057)
Furniture and fixtures		(86,893)	-	(2,411)	435	-	(9,127)	(97,996)
Facilities		(113,213)	-	(686)	422	-	(16,914)	(130,391)
IT equipment		(214,547)	-	(2,297)	9,731	-	(41,866)	(248,979)
Vehicles		(2,138)	-	(574)	484	-	(26)	(2,254)
Provision for recoverability		26,259	-	-	(26,259)	-	-	-
		(2,000,390)	**-**	**(16,755)**	**(16,422)**	**-**	**(263,975)**	**(2,297,542)**
		1,183,443	**189,330**	**9,287**	**358**	**(33,427)**	**(263,975)**	**1,085,016**

(In thousands of reais, unless otherwise indicated)

Consolidated

	Useful life (years)	Balance at 12/31/2023	Addition	Write-off	Exchange rate change (c)	Hyperinflationary accounting adjustment (d)	Transfers	Depreciation	Balance at 12/31/2024
Acquisition cost									
Properties	25	601,548	11,312	(60,927)	29,699	14,256	(6,394)	-	589,494
Leasehold improvements	10-20	2,876,630	34,582	(13,018)	90,815	30,565	105,642	-	3,125,216
Improvements to own properties	10	8,993	-	-	-	-	-	-	8,993
Machinery and equipment	10	3,079,796	53,763	(20,286)	60,080	123,088	232,180	-	3,528,621
Furniture and fixtures	10	299,860	7,072	(2,872)	17,282	10,800	1,882	-	334,024
Facilities	10	381,246	2,513	(1,340)	31,058	21,199	13,074	-	447,750
IT equipment	5	607,953	10,151	(6,175)	11,777	17,167	2,800	-	643,673
Vehicles	5	4,821	-	(19)	1,554	1,038	38	-	7,432
Land	-	91,673	2,219	(244)	-	-	-	-	93,648
Construction in progress (b)	-	216,633	355,994	(1,991)	-	-	(399,758)	-	170,878
Provision for recoverability	-	(6,383)	-	874	-	-	-	-	(5,509)
		8,162,770	**477,606**	**(105,998)**	**242,265**	**218,113**	**(50,536)**	**-**	**8,944,220**
Accumulated depreciation									
Properties		(119,297)	-	9,135	-	-	(14)	(28,170)	(138,346)
Leasehold improvements		(1,381,583)	-	5,235	(40,369)	(28,688)	2,561	(141,301)	(1,584,145)
Improvements to own properties		(8,622)	-	-	(2,854)	(263)	-	(19)	(11,758)
Machinery and equipment		(1,882,581)	-	16,598	(142,021)	(73,514)	460	(254,865)	(2,335,923)
Furniture and fixtures		(197,825)	-	3,334	(12,977)	(8,318)	530	(23,354)	(238,610)
Facilities		(166,498)	-	2,089	(35,239)	(20,866)	20	(26,263)	(246,757)
IT equipment		(396,841)	-	5,238	(31,610)	(14,358)	19	(68,416)	(505,968)
Vehicles		(4,649)	-	46	(984)	(650)	(67)	(134)	(6,438)
		(4,157,896)	**-**	**41,675**	**(266,054)**	**(146,657)**	**3,509**	**(542,522)**	**(5,067,945)**
		4,004,874	**477,606**	**(64,323)**	**(23,789)**	**71,456**	**(47,027)**	**(542,522)**	**3,876,275**

(In thousands of reais, unless otherwise indicated)

	Useful life (years)	Balance at 12/31/2022	Addition	Addition Merger	Write-off	Exchange rate change (c)	Hyperinflationary accounting adjustment (d)	Transfers	Depreciation	Balance at 12/31/2023
Acquisition cost										
Properties	25	590,708	-	-	(534)	(31,621)	21,599	21,396	-	601,548
Leasehold improvements	10-20	2,511,295	55,814	-	(40,566)	(134,009)	89,709	394,387	-	2,876,630
Improvements to own properties	10	8,668	-	347	(4,163)	-	-	4,141	-	8,993
Machinery and equipment	10	3,023,857	84,630	48	(14,279)	(200,933)	135,341	51,132	-	3,079,796
Furniture and fixtures	10	294,770	9,376	3	8,637	(14,203)	9,002	(7,725)	-	299,860
Facilities	10	260,005	18,961	-	(3,021)	(38,203)	25,884	117,620	-	381,246
IT equipment	5	606,828	12,571	(14)	(11,730)	(24,637)	16,487	8,448	-	607,953
Vehicles	5	6,106	122	-	(1,070)	(828)	466	25	-	4,821
Land	-	89,707	1,966	-	-	-	-	-	-	91,673
Construction in progress (b)	-	526,455	306,515	1	17,310	(36)	-	(633,612)	-	216,633
Provision for recoverability	-	(31,410)	-	-	25,027	-	-	-	-	(6,383)
		7,886,989	**489,955**	**385**	**(24,389)**	**(444,470)**	**298,488**	**(44,188)**	**-**	**8,162,770**
Accumulated depreciation										
Properties		(105,507)	-	-	405	87	2,042	-	(16,324)	(119,297)
Leasehold improvements		(1,289,756)	-	-	36,728	39,857	(30,820)	(9)	(137,583)	(1,381,583)
Improvements to own properties		(8,407)	-	-	4,158	393	(393)	-	(4,373)	(8,622)
Machinery and equipment		(1,683,964)	-	-	(5,917)	162,173	(105,821)	32	(249,084)	(1,882,581)
Furniture and fixtures		(171,463)	-	-	(8,876)	10,475	(7,410)	-	(20,551)	(197,825)
Facilities		(158,500)	-	-	2,342	36,815	(26,217)	6	(20,944)	(166,498)
IT equipment		(348,660)	-	-	10,827	19,869	(14,535)	(5)	(64,337)	(396,841)
Vehicles		(5,669)	-	-	985	695	(521)	-	(139)	(4,649)
Provision for recoverability		26,259	-	-	(26,259)	-	-	-	-	-
		(3,745,667)	**-**	**-**	**14,393**	**270,364**	**(183,675)**	**24**	**(513,335)**	**(4,157,896)**
		4,141,322	**489,955**	**385**	**(9,996)**	**(174,106)**	**114,813**	**(44,164)**	**(513,335)**	**4,004,874**

(a) Mergers of subsidiaries in the year.
(b) Mainly investments in appliances, equipment, and leasehold improvements.
(c) In the consolidation, property and equipment of foreign operations translated into Reais at the exchange rate at the balance sheet date.
(d) Pursuant to CPC 42/IAS 29 – Financial Reporting in Hyperinflationary Economies updates are made by applying a general price index in the period between the date of acquisition and the balance sheet date (Note 3.3).

Additions include R$ 2,715 in the parent company and R$ 2,761 in the consolidated with no cash effects in the year being installment payments (R$ 14,298 in the parent company and R$ 15,346 in the consolidated on December 31, 2023).

Management concluded that there were no indicators of impairment of property and equipment at December 31, 2024, requiring adjustments to provisions in the individual parent company and consolidated financial statements.

12 Intangible assets

Intangible assets comprise assets acquired from third parties, as follows:

- Goodwill from the acquisition of a subsidiary (Note 3.2.b) - indefinite useful life and therefore not amortized, but tested for impairment at least annually (item “Recoverability test” below).

- Other intangible assets acquired from third parties - software, technology and rights measured at the amount paid on acquisition and amortized on a straight-line over their useful lives and reviewed annually. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate.

- Intangible assets identified in the acquisition of subsidiaries - brands, customer relationships, non-compete agreement, among others, measured through valuation reports, amortized on a straight-line basis over their useful lives and are reviewed annually.

Amortization is recognized in the statement of income under general and administrative expenses and costs of services rendered, allocated according to the end use of each asset. Amortization methods, residual values and useful lives are reviewed annually and adjusted if necessary. The estimated useful lives are presented in the tables below and the amortization costs and expenses are shown in Note 24.

Gains and losses on disposals are calculated as the difference between the sale price and the residual book value and recognized in the statement of income under other income and expenses, net.

Research and development expenditures are recognized the statement of income as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company and its subsidiaries intend to and have sufficient resources to complete development and use or sell the asset. Other development expenditures are recognized in the statement of income as incurred. After the initial recognition, capitalized development expenditures are measured at cost less accumulated amortization and any accumulated impairment losses.

(In thousands of reais, unless otherwise indicated)

Parent Company

	Useful life (years)	Balance at 12/31/2023	Addition	Addition - merger (a)	Write-off	Transfers	Amortization	Balance at 12/31/2024
Acquisition cost								
Goodwill related to interest acquisitions:								
Acquisition of interest – Goodwill		2,157,874	-	-	-	-	-	2,157,874
		2,157,874	**-**	**-**	**-**	**-**	**-**	**2,157,874**
Intangible assets from acquisition of ownership interest:								
Brands	30	328,782	-	-	-	-	-	328,782
Client relationship	20	81,029	-	-	-	-	-	81,029
Non-compete agreement	7	702	-	-	-	-	-	702
		410,513	**-**	**-**	**-**	**-**	**-**	**410,513**
Other intangible assets:								
IT systems (b)	5	1,619,747	-	168	(555)	183,709	-	1,803,069
Commercial rights-of-use	5	5,488	-	-	-	-	-	5,488
Patents	33	96	-	6	-	-	-	102
Client exclusivity contracts (e)	15	180,735	35,000	-	(157,367)	-	-	58,368
Goodwill	5	1,243	-	-	-	-	-	1,243
Intangible assets in progress (d)		1,267	14,993	-	-	(14,993)	-	1,267
		1,808,576	**49,993**	**174**	**(157,922)**	**168,716**	**-**	**1,869,537**
		4,376,963	**49,993**	**174**	**(157,922)**	**168,716**	**-**	**4,437,924**
Intangible assets from acquisition of ownership interest:								
Brands		(124,558)	-	-	-	-	(10,996)	(135,554)
Relationship with clients		(44,872)	-	-	-	-	(3,119)	(47,991)
Non-compete agreement		(702)	-	-	-	-	-	(702)
Software		-	-	-	-	-	-	-
		(170,132)	**-**	**-**	**-**	**-**	**(14,115)**	**(184,247)**
Other intangible assets:								
IT systems		(934,794)	-	(129)	555	-	(245,433)	(1,179,801)
Commercial rights-of-use		(5,125)	-	-	-	-	(363)	(5,488)
Trademarks and patents		(76)	-	(6)	19,833	-	(3)	19,748
Client exclusivity contract		(30,719)	-	-	-	-	(12,186)	(42,905)
Goodwill		(553)	-	-	-	-	(117)	(670)
		(971,267)	**-**	**(135)**	**20,388**	**-**	**(258,102)**	**(1,209,116)**
		(1,141,399)	**-**	**(135)**	**20,388**	**-**	**(272,217)**	**(1,393,363)**
		3,235,564	**49,993**	**39**	**(137,534)**	**168,716**	**(272,217)**	**3,044,561**

(In thousands of reais, unless otherwise indicated)

	Useful life (years)	Balance at 12/31/2022	Addition (b)	Addition - merger (a)	Write-off	Transfers	Amortization	Balance at 12/31/2023
Acquisition cost								
Goodwill related to interest acquisitions:								
Acquisition of interest - Goodwill		2,055,275	-	102,599	-	-	-	2,157,874
		2,055,275	**-**	**102,599**	**-**	**-**	**-**	**2,157,874**
Intangible assets from acquisition of ownership interest:								
Brands	30	312,834	-	15,948	-	-	-	328,782
Client relationship	20	74,473	-	6,556	-	-	-	81,029
Non-compete agreement	7	702	-	-	-	-	-	702
		388,009	-	22,504	-	-	-	**410,513**
Other intangible assets:								
IT systems (b)	5	1,416,360	-	490	-	202,897	-	1,619,747
Commercial rights-of-use	5	6,162	-	-	(674)	-	-	5,488
Patents	33	96	-	-	-	-	-	96
Client exclusivity contracts (e)	15	24,051	156,684	-	-	-	-	180,735
Goodwill	5	1,243	-	-	-	-	-	1,243
Intangible assets in progress (d)		1,267	169,470	-	-	(169,470)	-	1,267
		1,449,179	**326,154**	**490**	**(674)**	**33,427**	**-**	**1,808,576**
		3,892,463	**326,154**	**125,593**	**(674)**	**33,427**	**-**	**4,376,963**
Intangible assets from acquisition of ownership interest:								
Brands		(110,860)	-	(3,234)	-	-	(10,464)	(124,558)
Relationship with clients		(40,544)	-	(1,448)	-	-	(2,880)	(44,872)
Non-compete agreement		(667)	-	-	-	-	(35)	(702)
		(152,071)	**-**	**(4,682)**	**-**	**-**	**(13,379)**	**(170,132)**
Other intangible assets:								
IT systems		(699,186)	-	(479)	-	-	(235,129)	(934,794)
Commercial rights-of-use		(4,729)	-	-	517	-	(913)	(5,125)
Trademarks and patents		(73)	-	-	-	-	(3)	(76)
Client exclusivity contract		(16,466)	-	-	-	-	(14,253)	(30,719)
Goodwill		(416)	-	-	-	-	(137)	(553)
		(720,870)	**-**	**(479)**	**517**	**-**	**(250,435)**	**(971,267)**
		(872,941)	**-**	**(5,161)**	**517**	**-**	**(263,814)**	**(1,141,399)**
		3,019,522	**326,154**	**120,432**	**(157)**	**33,427**	**(263,814)**	**3,235,564**

(In thousands of reais, unless otherwise indicated)

Consolidated

	Useful life (years)	Balance at 12/31/2023	Addition	Write-off	Exchange-rate change (f)	Hyper inflationary accounting adjustment (c)	Transfers	Amortization	Balance at 12/31/2024
Acquisition cost									
Goodwill related to interest acquisitions:									
Acquisition of interest - Goodwill		8,944,923	-	(229,789)	566	-	(135,739)	-	8,579,961
		8,944,923	**-**	**(229,789)**	**566**	**-**	**(135,739)**	**-**	**8,579,961**
Intangible assets from acquisition of ownership interest:									
Brands	30	775,232	18	(1,933)	59,004	33,960	8,917	-	875,198
Client relationship	20	383,201	-	(55,552)	(14)	-	-	-	327,635
Appreciation of assets	5	1,791	-	-	-	-	-	-	1,791
Non-compete agreement	7	36,391	-	(5,243)	-	-	-	-	31,148
Software	5	42,056	-	-	-	-	-	-	42,056
		1,238,671	**18**	**(62,728)**	**58,990**	**33,960**	**8,917**	**-**	**1,277,828**
Other intangible assets:									
IT systems (b)	5	1,860,049	16,672	(17,116)	2,428	15,951	194,617	-	2,072,601
Commercial rights-of-use	5	5,517	-	-	-	-	-	-	5,517
Patents	33	1,888	-	-	-	-	-	-	1,888
Client exclusivity contracts (e)	15	205,327	35,000	(157,367)	-	-	-	-	82,960
Goodwill	5	6,666	-	-	-	-	-	-	6,666
Intangible assets in progress (d)		9,350	17,589	-	-	-	(15,696)	-	11,243
		2,088,797	**69,261**	**(174,483)**	**2,428**	**15,951**	**178,921**	**-**	**2,180,875**
		12,272,391	**69,279**	**(467,000)**	**61,984**	**49,911**	**52,099**	**-**	**12,038,664**
Accumulated amortization									
Intangible assets from acquisition of ownership interest:									
Brands		(200,409)	-	201	(19,658)	(27,142)	(5,550)	(29,427)	(281,985)
Relationship with clients		(184,745)	-	3,410	38,214	-	-	(38,409)	(181,530)
Appreciation of assets		(1,452)	-	-	-	-	-	(24,163)	(25,615)
Non-compete agreement		(27,483)	-	4,194	-	-	-	(5,242)	(28,531)
Software		(13,138)	-	-	-	-	-	-	(13,138)
		(427,227)	**-**	**7,805**	**18,556**	**(27,142)**	**(5,550)**	**(97,241)**	**(530,799)**
Other intangible assets:									
IT systems		(1,053,738)	-	13,150	(21,098)	(10,521)	478	(293,484)	(1,365,213)
Commercial rights-of-use		(5,125)	-	-	-	-	-	(363)	(5,488)
Trademarks and patents		(408)	-	-	-	-	-	(295)	(703)
Client exclusivity contract (d)		(48,773)	-	19,833	-	-	-	(16,802)	(45,742)
Goodwill		(2,163)	-	-	-	-	-	(1,201)	(3,364)
		(1,110,207)	**-**	**32,983**	**(21,098)**	**(10,521)**	**478**	**(312,145)**	**(1,420,510)**
		(1,537,434)	**-**	**40,788**	**(2,542)**	**(37,663)**	**(5,072)**	**(409,386)**	**(1,951,309)**
		10,734,957	**69,279**	**(426,212)**	**59,442**	**12,248**	**47,027**	**(409,386)**	**10,087,355**

(In thousands of reais, unless otherwise indicated)

	Useful life (years)	Balance at 12/31/2022	Addition	Addition Merger	Write-off	Exchange-rate change (f)	Hyperinflationary accounting adjustment (c)	Transfers	Amortization	Balance at 12/31/2023
Acquisition cost										
Goodwill related to interest acquisitions:										
Acquisition of interest - Goodwill		9,024,261	68,785	7,491	(43,018)	(43,918)	-	(68,678)	-	8,944,923
		9,024,261	**68,785**	**7,491**	**(43,018)**	**(43,918)**	**-**	**(68,678)**	**-**	**8,944,923**
Intangible assets from acquisition of ownership interest:										
Brands	30	764,280	1,445	-	-	(92,032)	18,943	82,596	-	775,232
Client relationship	20	485,820	-	-	-	(22,921)	-	(79,698)	-	383,201
Appreciation of assets	5	-	-	-	-	(154)	-	1,945	-	1,791
Non-compete agreement	7	23,274	-	-	-	45	-	13,072	-	36,391
Software	5	23,099	-	-	-	-	-	18,957	-	42,056
		1,296,473	**1,445**	**-**	**-**	**(115,062)**	**18,943**	**36,872**	**-**	**1,238,671**
Other intangible assets:										
IT systems (b)	5	1,529,104	62,431	66	(2,281)	(27,533)	7,962	290,300	-	1,860,049
Commercial rights-of-use	5	8,685	-	-	(674)	-	-	(2,494)	-	5,517
Patents	33	629	-	-	(5)	5	-	1,259	-	1,888
Client exclusivity contracts (e)	15	52,507	156,684	-	(1,988)	124	-	(2,000)	-	205,327
Goodwill	5	6,666	-	-	-	-	-	-	-	6,666
Intangible assets in progress (d)		6,205	179,903	-	-	-	-	(176,758)	-	9,350
		1,603,796	**399,018**	**66**	**(4,948)**	**(27,404)**	**7,962**	**110,307**	**-**	**2,088,797**
		11,924,530	**469,248**	**7,557**	**(47,966)**	**(186,384)**	**26,905**	**78,501**	**-**	**12,272,391**
Accumulated amortization										
Intangible assets from acquisition of ownership interest:										
Brands		(216,360)	-	-	-	31,355	(14,832)	31,602	(32,174)	(200,409)
Relationship with clients		(146,961)	-	-	-	8,598	-	(2,732)	(43,650)	(184,745)
Appreciation of assets		-	-	-	-	-	-	(1,086)	(366)	(1,452)
Non-compete agreement		(22,685)	-	-	-	-	-	518	(5,316)	(27,483)
Software		(6,168)	-	-	-	-	-	-	(6,970)	(13,138)
		(392,174)	**-**	**-**	**-**	**39,953**	**(14,832)**	**28,302**	**(88,476)**	**(427,227)**
Other intangible assets:										
IT systems		(729,634)	-	-	1,540	16,557	(6,519)	(63,548)	(272,134)	(1,053,738)
Commercial rights-of-use		(4,728)	-	-	517	-	-	-	(914)	(5,125)
Trademarks and patents		(164)	-	-	-	-	-	51	(295)	(408)
Client exclusivity contract		(30,762)	-	-	-	-	-	858	(18,869)	(48,773)
Goodwill		(1,052)	-	-	-	-	-	-	(1,111)	(2,163)
		(766,340)	**-**	**-**	**2,057**	**16,557**	**(6,519)**	**(62,639)**	**(293,323)**	**(1,110,207)**
		(1,158,514)	**-**	**-**	**2,057**	**56,510**	**(21,351)**	**(34,337)**	**(381,799)**	**(1,537,434)**
		10,766,016	**469,248**	**7,557**	**(45,909)**	**(129,874)**	**5,554**	**44,164**	**(381,799)**	**10,734,957**

(a) Mergers of subsidiaries in the year.
(b) Mainly investments in systems development.
(c) Pursuant to CPC 42/IAS 29 – Financial Reporting in Hyperinflationary Economies updates are made by applying a general price index in the year between the date of acquisition up to the balance sheet date (Note 3.3).
(d) Expenses classified as intangible assets in progress during the development period transferred to a specific item in the intangible group when they are available for use.
(e) On April 6, 2023, the Company entered into an exclusive agreement with Unimed-Rio to provide diagnostic services for its patients in the amount of R$ 170,000, recognized at present value in intangible assets in the amount of R$ 156,684. Under the terms of the agreement, Unimed-Rio directs its patients to DASA for a period of 10 years. In 2024, following an agreement between the parties, this exclusive agreement was terminated.
(f) In the consolidation, intangible assets of foreign operations are translated into Reais at the exchange rate the balance sheet date.
(g) At December 2023, classified as discontinued operations in Uruguay, writing off R$ 37,938 for goodwill recognized on the acquisition.

Additions include R$ 5,242 in the parent company and R$ 5,625 in the consolidated with no cash effects in the year being installment payments (R$ 131,747 in the parent company and R$ 132,608 in the consolidated on December 31, 2023).

(In thousands of reais, unless otherwise indicated)

Recoverability test (Consolidated)

For the purposes of the recoverability test, the cash-generating units ("CGU's") correspond to the internal reports used by the Company's management in decision-making (see Note 28 – Information by business segment).

Goodwill is allocated to CGU's, and the book value of the segment and the cash flow projection are presented below:

	12/31/2024			12/31/2023		
	Goodwill	Book value	Cash flow	Goodwill	Book value	Cash flow
Hospitals and oncology (BU1)	5,334,411	3,112,209	9,328,874	5,534,189	3,379,892	12,636,725
Diagnosis and care coordination (BU2)	3,245,550	3,788,097	9,421,745	3,337,986	4,083,454	16,870,813
	8,579,961	**6,900,306**	**18,750,619**	**8,872,175**	**7,463,345**	**29,507,539**

Management tests the recoverability of goodwill of acquired subsidiaries annually, including the intangible assets of these CGU's. This requires management's judgment in determining future estimates as to the ability to generate discounted future cash flows. Projected cash flows are consistent with most recent long-term forecasts approved by Management. The projections consider market expectations, use of judgments related to the income growth and into perpetuity, estimates of future investments, working capital and discount rates for CGUs.

The recoverable value of an asset or CGU is the greater of its value in use and its fair value less costs to sell. The fair value less costs to sell reflects the price that would be received for the sale of an asset in a non-forced transaction between market players, excluding expenses to remove the asset, incremental direct expenses to bring the asset to sale condition, legal expenses and taxes. Value in use considers estimated future cash flows discounted to present value at a discount rate that reflects current market conditions for the period and the specific risks of the asset or CGU. An impairment loss is recognized when the book value of an asset or its CGU exceeds its recoverable value. Asset impairment losses are recognized in the statement of income. An impairment loss related to goodwill is not reversed. As to other assets, impairment losses are reversed only if the new book value of the asset does not exceed the book value that would have been calculated, net of depreciation or amortization, had the value loss had not been recognized.

After making the future projections, the book value, including goodwill, is compared to the recoverable amount determined by the projections made for the CGU.

The following assumptions were used for the CGU's and brands analyzed and represent management's best estimate and judgment:

- Cash flow projections are based on management's expectations and reflect the best information available at the time. Although there may be factors, risks or uncertainties, whether known or not, that could result in differences between current data and any projections, management believes that it is reasonably possible that such factors would not cause the total book value to exceed the recoverable amount of the CGU. The projection are forecast over nine years plus the residual value calculated by the perpetuation of the cash balance in the ninth year, discounted to the present value by the Weighted Average Cost of Capital (WACC) of 15.2% (12.0% in 2023). The pre-tax WACC on December 31, 2024 was 17.0% (on December 31, 2023 was 14.6%).

- Income: projected for the coming years considering historical growth in the volume of services provided and inflation projections based on macroeconomic projections of financial institutions, excluding future units.

- Expenses: projected over the same period, taking account of the Earnings Before Interest, Tax, Depreciation and Amortization ("EBITDA") growth rate.

- Capital investment: considers the historical average percentage of investment in asset maintenance.

- Growth rate in perpetuity: considers the IPCA rate projected by The Brazilian Central Bank -BACEN of 3.8% p.a. (3.5% for December 31, 2023).

- Evaluation period: the assessment of value in use is carried out for a period of nine years and, plus the perpetuity of the assumptions based on the ability of the Company to continue operating as a going concern for the foreseeable future.

Sensitivity analysis:

The main risks related to the implementation of the business plan are: (i) success in negotiating with operators, mainly impacting on the Company's working capital and pricing on-lending negotiation projections; (ii) macroeconomic factors which, in turn, have an impact on the price of inputs and medicines; and (iii) health sector scenarios such as: verticalization, market consolidation, changes in regulations and regulatory agency standards, among other factors.

Management carried out a sensitivity analysis on the impairment test of the CGU's to which the goodwill was allocated concluding that changes in the main assumptions do not alter the recoverable amount which is still greater than the book value of the corresponding CGU's.

13 Right-of-use assets and lease liabilities

A right-of-use asset and a lease liability are recognized when a lease transfers the right to control the use of an asset for a certain period in exchange for consideration. At lease inception, the present value of the cash flow of future contract consideration is measured, with assets and liabilities recognized at the same amount. The amortization of the right-of-use asset is recognized in the statement of income over the estimated term of the contract and the lease liability plus interest, net of payments. Interest is recognized in the statement of income using the effective rate method. The remeasurement of assets and liabilities based on the contractual adjustment index is recognized in the balance sheet with no effect on the statement of income. If the contract is canceled, the asset and the corresponding liability are written off to the statement of income under other expenses and income, net, considering, if applicable, the penalties provided for in the contract.

DASA Group leases property including: service units, diagnosis, warehouses, administrative offices, hospitals and technical operational centers. The terms of the contracts vary between five and ten years and are negotiated individually.

(In thousands of reais, unless otherwise indicated)

Changes in the right-of-use asset balances were:

Right-of-use assets	Parent Company	Consolidated
Balance at December 31, 2022	**962,194**	**2,331,903**
Addition by merger of subsidiaries, net	7,276	-
Additions	52,261	117,041
Write-off	-	(159)
Remeasurement (b)	76,469	426,440
Amortization	(208,345)	(401,170)
Balance at December 31, 2023	**889,855**	**2,474,055**
Addition by merger of subsidiaries, net	3,769	-
Additions	106,718	233,526
Write-off	(188,949)	(219,074)
Remeasurement (b)	156,981	242,078
Amortization	(209,201)	(414,910)
Balance at December 31, 2024	**759,173**	**2,315,675**

The changes in lease liabilities were:

Lease liabilities	Parent Company	Consolidated
Balance at December 31, 2022	**963,899**	**2,441,808**
Addition by merger of subsidiaries, net	5,964	-
Additions	52,261	117,041
Write-off	-	(159)
Interest accrued (a)	88,898	217,993
Interest paid	(88,898)	(217,993)
Payments of principal	(170,592)	(341,939)
Remeasurement (b)	76,469	426,440
Balance at December 31, 2023	**928,001**	**2,643,191**
Addition by merger of subsidiaries, net	4,678	-
Additions	106,718	233,526
Write-off	(146,267)	(161,219)
Interest accrued (a)	103,309	305,688
Interest paid	(103,309)	(305,688)
Payments of principal	(197,213)	(361,198)
Remeasurement (b)	156,981	242,078
Balance at December 31, 2024	**852,898**	**2,596,378**
Current	220,123	343,384
Non-current	632,775	2,252,994

(a) Interest is recorded under “Financial expenses.”
(b) Remeasurement originates from changes in future lease payments resulting from adjustments in monthly amounts by the inflation index of each agreement and/or its effectiveness period.

For the calculation of lease contracts, the following market funding rates were used for discounting:

Term of agreements (years)	Rate
01–02	11.0%
03–04	11.3%
05–09	11.2%
>10	11.1%
Weighted average	**11.2%**

(In thousands of reais, unless otherwise indicated)

The maturity dates of non-current installments are presented below:

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
01–02 years	96,691	148,214	151,148	175,940
02–03 years	211,032	294,761	312,163	359,092
03–04 years	215,921	138,590	999,685	350,704
>04 years	109,131	164,241	789,998	1,378,857
	632,775	**745,806**	**2,252,994**	**2,264,593**

Considering a projected inflation rate of 4.5% in 2024 (3.6% in 2023), the impacts on right-of-use assets, lease liabilities, depreciation and financial expenses would be:

	12/31/2024		12/31/2023	
Cash flow	Book value	Projected inflation	Book value	Projected inflation
Right-of-use assets, net	2,315,674	2,418,780	2,474,056	2,563,123
Lease liabilities	2,596,378	2,711,982	2,643,192	2,738,347
Depreciation expense	414,910	433,384	401,169	415,611
Financial expenses	305,688	319,299	197,609	204,723

14 Suppliers

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Domestic suppliers	624,035	654,268	1,457,720	1,558,740
Foreign suppliers	19,637	21,272	25,127	26,245
	643,672	**675,540**	**1,482,847**	**1,584,985**
Current	599,103	628,802	1,438,273	1,538,242
Non-current	44,569	46,738	44,574	46,743

15 Loans and financing

	Parent Company		Consolidated	
Modality	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Working capital (a)	-	11,958	9,950	191,775
Leases (b)	-	-	58	495
	-	**11,958**	**10,008**	**192,270**
Current	-	4,743	2,609	122,966
Non-current	-	7,215	7,399	69,304

(a) There are no guarantees.
(b) Backed by the underlying financed asset.

(In thousands of reais, unless otherwise indicated)

Changes in loans and financing were as follows:

	Parent Company	Consolidated
Balance at December 31, 2022	**2,124,403**	**2,559,398**
Interest accrued and exchange rate changes	158,999	187,850
Interest paid	(270,605)	(305,909)
Amortization of principal	(2,001,325)	(2,249,779)
Merger of subsidiary	486	-
Acquisition of subsidiary	-	710
Balance at December 31, 2023	**11,958**	**192,270**
Interest accrued	537	12,155
Exchange-rate change	-	5,514
Interest paid	(340)	(13,130)
Amortization of principal	(12,155)	(186,801)
Balance at December 31, 2024	**-**	**10,008**
Current	-	2,609
Non-current	-	7,399

Loans classified in non-current liabilities mature as follows:

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
01–02 years	-	4,331	7,399	45,527
02–03 years	-	2,884	-	23,777
	-	**7,215**	**7,399**	**69,304**

On December 31, 2024, the DASA Group had no loan and financing agreements with financial leverage covenants.

16 Debentures

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Non-convertible debentures	10,172,175	10,150,000	10,172,175	10,350,000
Interest accrued	323,590	205,401	323,590	206,795
Transaction costs	(108,764)	(97,366)	(108,764)	(97,628)
	10,387,001	**10,258,035**	**10,387,001**	**10,459,167**
Current	935,242	1,194,698	935,242	1,395,830
Non-current	9,451,759	9,063,337	9,451,759	9,063,337

(In thousands of reais, unless otherwise indicated)

Information on debenture placements:

Last maturity date	Issue	Principal value	Average financial charges (*)	Balance at 12/31/2024 (**)
10/20/2025	14th issue of debentures S1	237,825	CDI+2.10%	243,458
06/10/2026	11th issue of debentures	400,000	CDI+1.03%	402,544
10/30/2026	15th issue of debentures S1	1,000,000	CDI+1.60%	1,018,362
12/10/2026	10th issue of debentures S3	400,000	CDI+1.52%	402,617
04/20/2027	16th issue of debentures	2,000,000	CDI+1.60%	2,040,500
10/13/2027	17th issue of debentures S1	333,334	CDI+0.80%	341,298
10/20/2027	14th issue of debentures S2	124,350	CDI+2.40%	127,259
10/20/2027	18th issue of debentures	1,000,000	CDI+1.60%	1,009,033
10/30/2028	15th issue of debentures S2	285,359	CDI+1.70%	290,368
12/22/2028	20th issue of debentures	1,300,000	CDI+2.25%	1,291,812
01/15/2029	21st issue of debentures S1	133,805	CDI+1.63%	137,364
01/15/2029	21st issue of debentures S2	551,248	CDI+1.97%	565,174
10/10/2029	17th issue of debentures S2	419,184	CDI+1.05%	453,770
01/15/2031	21st issue of debentures S3	124,430	CDI+1.96%	130,318
01/15/2031	21st issue of debentures S4	690,427	CDI+2.36%	709,539
10/30/2031	15th issue of debentures S3	714,641	CDI+2.05%	726,000
10/13/2032	17th issue of debentures S3	247,482	CDI+1.22%	277,287
01/16/2034	21st issue of debentures S5	210,090	CDI+2.13%	220,298
		10,172,175		**10,387,001**
Current				935,242
Non-current				9,451,759

(*) Considering derivative financial instruments contracted (Note 29.a.3).
(**) Principal and interest, net of transaction costs.

Changes in debenture balances:

	Parent Company	Consolidated
Balance at December 31, 2022	**8,499,835**	**8,902,701**
Funding (a)	3,300,000	3,300,000
Interest accrued and exchange rate changes	1,330,009	1,378,039
Interest paid	(1,324,838)	(1,374,866)
Amortization of principal (b)	(1,521,667)	(1,721,667)
Transaction costs	(25,304)	(25,040)
Balance at December 31, 2023	**10,258,035**	**10,459,167**
Funding (see Note 2.b)	1,710,000	1,710,000
Interest accrued	1,283,001	1,299,573
Inflation adjustment	47,314	47,314
Interest paid	(1,212,126)	(1,230,092)
Amortization of principal (c)	(1,687,825)	(1,887,825)
Transaction costs	(11,398)	(11,136)
Balance at December 31, 2024	**10,387,001**	**10,387,001**

(a) Placement of R$ 1,300,000 on December 18, 2023 and R$ 2,000,000 on July 17, 2023.

(b) On December 28, 2023, the optional early amortization of 1,100,000 simple debentures, not convertible into shares with real guarantee, in a single series, of the 19th issue of the Company, was completed, with a nominal unit value of R$ 1, amounting to R$ 1,100,000.

(c) On February 6, 2024, the early redemption of 900,000 simple debentures, not convertible into shares with real guarantee, in a single series, of the 19th issue of the Company, took place with a nominal unit value of R$ 1, amounting to R$ 900,000.

(In thousands of reais, unless otherwise indicated)

Debentures classified in non-current liabilities mature as follows:

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
01–02 years	2,438,039	839,928	2,438,039	839,928
02–03 years	2,374,493	2,666,315	2,374,493	2,666,315
03–04 years	1,566,512	3,257,094	1,566,512	3,257,094
>04 years	3,072,715	2,300,000	3,072,715	2,300,000
	9,451,759	**9,063,337**	**9,451,759**	**9,063,337**

Debentures include restrictive financial clauses ("covenants"). Failure to comply with obligations or restrictions for two consecutive quarters may lead to the early maturity of the related debts and cross-default for other contractual obligations.

The restrictive covenants are based on financial indices calculated based on the consolidated financial statements, as follows:

1- Net debt/EBITDA - maximum ratio of 4.00
2- EBITDA/Financial income (expense) - minimum ratio of 1.50

Financial net debt for covenants: being: (i) the sum of all consolidated debts of the Company to individuals and/or legal entities for: (a) loans and financing with third parties; (b) debts arising from issues of fixed-income securities, in circulation in the local and/or international capital markets; (c) net balance of derivative transactions (i.e. liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued by the Company; and (e) the balance of credit assignment operations up to the limit of the Company's co-obligation; less (ii) the sum of (a) the amount available in the cash; (b) the net balances of the bank checking accounts; and (c) balances of interest earning bank deposits. For the purposes of calculating this financial ratio, on December 31, 2024, R$ 4,869 corresponds to the net financial cash for discontinued operations' covenants.

Adjusted EBITDA (Earnings before interest, taxes, depreciation and amortization) for covenants: a non-accounting measure determined over the four preceding quarters, reflecting the Company's consolidated profit before net financial expenses, income tax and social contribution on income, depreciation, amortization, and stock option plan expenses. In case of acquisition(s), the EBITDA generated in the period of 12 months preceding the end of each quarter of the calendar year by the acquiree(s) will be considered for the purposes of calculating the Company's EBITDA. For the purposes of calculating this financial ratio, on December 31, 2024, the negative amount of R$ 103 corresponds to the Adjusted EBITDA for covenant purposes in the last 12 months of discontinued operations.

Financial income (expense) for covenants

10th issue: This is the difference between the Company's consolidated financial income and financial expenses for the four quarters preceding the current quarter, excluding interest on equity for the purpose of calculating financial commitments (if negative or, if positive are ignore). This calculation excludes the interest disbursed and/or provisioned due to confession of debt with a private pension entity, as well as foreign exchange effects and charges on debt and noncash items, based on its consolidated financial statements. For the purposes of calculating this financial ratio, on December 31, 2024, the amount of R$ 91 in expense for the purposes of covenants (10th Issue) of discontinued operations.

(In thousands of reais, unless otherwise indicated)

Other issues: This is the difference between the Company's consolidated financial income and the financial expenses for the four quarters preceding the current quarter, relating exclusively to (i) the financial expenses relating to the debts from individuals and/or legal entities, limited to (a) loans and financing with third parties; (b) debts arising from issues of fixed-income securities, in circulation in the domestic and/or international capital markets; (c) net balance of derivative transactions (i.e. liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued; and (e) the balance of credit assignment operations up to the limit of the Company's co-obligation; and (ii) financial income referring to (a) the amount available to the cash; (b) the net balances of bank checking accounts; and (c) interest earning bank deposits. For the purposes of calculating this financial ratio, on December 31, 2024, R$ 1,317 corresponds to the financial income (expense) for the purposes of covenants (other issues) of discontinued operations.

On December 31, 2024, and December 31, 2023, DASA Group was fully in compliance with contractual terms and conditions. The net debt/EBITDA financial covenant ratio was 3.55x, below the limit provided for in the deeds of 4.0x.

17 Social charges and labor obligations

Refer to labor obligations, plus respective charges and short-term employee benefits and are recognized as expenses as the service is rendered, allocated as a cost or expense depending on the employee's activity. The provision for the payment of bonuses in kind and profit sharing is recognized on an accrual basis when the Company and its subsidiaries has a legal or constructive obligation to pay these amounts as a result of the service rendered by the employee based on estimates of the achievement of specific targets and objectives established and the obligation can be reliably estimated.

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Provision for vacation	104,537	122,623	290,586	317,648
Provision for profit sharing	101,511	1,677	163,013	3,929
Salaries and wages	50,725	57,322	158,725	156,547
Social charges	32,945	36,246	91,249	91,805
Other	21,358	12,213	61,610	43,668
	311,076	**230,081**	**765,183**	**613,597**

The DASA Group does not grant post-employment benefits defined as Free Benefit Generation Plan (PGBL), Free Benefit Generating Life Insurance (VGBL), defined benefit pension plan and/or any post-employment retirement or assistance plan, termination benefits or other long-term benefits. The remuneration of employees and executives includes a share-based payment plan (Note 21).

(In thousands of reais, unless otherwise indicated)

18 Taxes payable

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
IRRF (a) payable	20,339	25,181	69,936	52,038
Service tax (ISS) payable	19,295	14,240	92,422	68,006
PIS and COFINS payable	6,245	1,122	29,720	29,118
IRPJ/CSLL payable	2,657	9,363	6,402	20,588
INSS payable	21,110	12,755	28,580	19,938
Installment payment of ISS	-	497	722	1,911
Installments – Federal taxes	1,387	1,351	107,513	132,720
Refis (b) – Ímpar	-	-	5,328	21,702
Installment payment - INSS	-	-	5,051	45,004
Other taxes payable	1,647	-	12,803	33,807
	72,680	**64,509**	**358,477**	**424,832**
Current	72,680	64,033	283,053	316,818
Non-current	-	476	75,424	108,014

(a) IRRF – Withholding income tax.
(b) Refis - Tax Recovery Program.

Taxes in installments classified in non-current liabilities are due as follows:

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
01–02 years	-	476	21,079	40,989
02–03 years	-	-	20,473	26,029
03–04 years	-	-	16,095	40,995
>04 years	-	-	17,777	-
	-	**476**	**75,424**	**108,014**

(In thousands of reais, unless otherwise indicated)

19 Payable - acquisition of subsidiaries

These are payables to the selling party for the acquisition of shares or quotas of the acquirees.

Parent Company	Not collateralized by interest earning bank deposits	Not collateralized by interest earning bank deposits - International	Collateralized by interest earning bank deposits	Contingent consideration	Total
Balance at December 31, 2022	**159,370**	**2,511**	**22,366**	**8,335**	**192,582**
Renegotiation	(29,807)	46,006	-	-	16,199
Acquisitions	-	-	-	1,019	1,019
Indexation and exchange-rate change	18,957	(1,721)	2,301	920	20,457
Payments	(61,442)	(2,500)	(18,192)	(1,717)	(83,851)
Balance at December 31, 2023	**87,078**	**44,296**	**6,475**	**8,557**	**146,406**
Renegotiation	-	-	(27)	4,625	4,598
Indexation	6,440	-	-	1,360	7,800
Exchange-rate change	-	5,176	-	255	5,431
Payments	(34,225)	(38,656)	-	(1,121)	(74,002)
Balance at December 31, 2024	**59,293**	**10,816**	**6,448**	**13,676**	**90,233**
Current					70,109
Non-current					20,124

Consolidated	Not collateralized by interest earning bank deposits	Not collateralized by interest earning bank deposits - International	Collateralized by interest earning bank deposits	Contingent consideration	Total
Balance at December 31, 2022	**1,222,113**	**2,511**	**22,490**	**67,478**	**1,314,592**
Renegotiation	(29,807)	46,006	-	-	16,199
Acquisitions	23,665	-	-	1,019	24,684
Indexation and exchange-rate change	148,155	(1,721)	2,306	920	149,660
Payments	(215,779)	(2,500)	(18,191)	(1,717)	(238,187)
Balance at December 31, 2023	**1,148,347**	**44,296**	**6,605**	**67,700**	**1,266,948**
Renegotiation	-	-	560	4,625	5,185
Indexation	142,820	-	-	1,360	144,180
Exchange-rate change	-	5,176	-	255	5,431
Payments	(313,957)	(38,656)	-	(1,121)	(353,734)
Balance at December 31, 2024	**977,210**	**10,816**	**7,165**	**72,819**	**1,068,010**
Current					523,426
Non-current					544,584

The amounts classified in non-current liabilities are due as follows :

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
01–02 years	20,124	67,776	53,890	183,720
02–03 years	-	-	445,354	102,281
03–04 years	-	-	34,861	434,906
04–05 years	-	-	3,498	31,442
>05 years	-	-	6,981	9,453
	20,124	**67,776**	**544,584**	**761,802**

(In thousands of reais, unless otherwise indicated)

Put and call option - non-controlling shareholders

As part of the agreement to acquire equity interests, put options were issued by the Company or its subsidiaries in favor of the non-controlling shareholders and call options were issued by the sellers in favor of the Company or its subsidiaries. This may result in acquisition by the Company or its subsidiaries of the remaining shares of non-controlling shareholders, in the following companies: Fernando Henriques Pinto Junior & Cia Ltda. ("Padrão"), CPClin – Centro de Pesquisa Clínicas Ltda. ("CPClin") and Nossa Senhora do Carmo Participações ("Carmo Group"). Call and put option balances are recorded under other accounts payable and provisions and other credits.

20 Provision for tax, social security, labor and civil claims, contingencies and judicial deposits

The Company and its subsidiaries are party to several ongoing lawsuits. Management, under the advice of its legal specialists in the area, assesses the status of the proceedings, the situation applying a level of judgment to each specific case. The main uncertainties relate to the likelihood and magnitude of cash outflows.

a) Tax, social security, labor and civil provision and judicial deposits

A provision is made for tax, social security, labor and civil lawsuits when the prognosis, as determined by management under the advice of legal counsel, concludes that the risk of loss is probable (chances of loss greater than 50%).

Due to the significant volume of labor lawsuits, the provision is based on an average of the payments made over the total amounts claimed in the lawsuits over in the last three years and is applied to current lawsuits. Proceedings in which the expectation of loss is considered individually material are analyzed by internal and external legal advisors. Currently, no labor claim is considered individually material.

Some of the tax, social security, labor and civil provisions have all or part of judicial deposits related to them.

The provisions and judicial deposits are as follows:

	Parent Company				Consolidated			
	12/31/2024		12/31/2023		12/31/2024		12/31/2023	
	Provision	**Judicial deposit**	**Provision**	**Judicial deposit**	**Provision**	**Judicial deposit**	**Provision**	**Judicial deposit**
Labor and civil	16,214	27,557	45,094	19,101	111,291	83,307	175,775	66,346
Tax and social security claims	64,174	33,695	64,525	40,552	76,333	48,837	283,842	51,814
	80,388	**61,252**	**109,619**	**59,653**	**187,624**	**132,144**	**459,617**	**118,160**

(In thousands of reais, unless otherwise indicated)

Changes in tax, social security, labor and civil provisions were as follows:

	Labor and civil		Tax and social security	
	Parent Company	Consolidated	Parent company	Consolidated
Balance at December 31, 2022	**34,041**	**121,014**	**91,959**	**280,234**
Additions	47,032	65,713	39,055	39,300
Merger of subsidiaries	49	-	-	-
Additions (reversals) relating to former management (a)	3,552	94,156	3,131	44,999
Write-off/Settlement	(47,200)	(111,871)	(56,756)	(66,855)
Update (reversal of update)	7,620	6,763	(12,864)	(13,835)
Balance at December 31, 2023	**45,094**	**175,775**	**64,525**	**283,842**
Additions	39,838	80,205	47,880	56,451
Merger of subsidiaries	87	-	-	-
Additions (reversals) relating to former management (a)	(402)	(20,540)	(717)	(212,300)
Write-off/Settlement	(57,900)	(114,601)	(48,620)	(53,668)
Update (reversal of update)	(10,503)	(9,548)	1,106	2,008
Balance at December 31, 2024	**16,214**	**111,291**	**64,174**	**76,333**

(a) Some agreements for acquisition of subsidiaries, include clauses covering contingent lawsuits, where the responsibility for payment, in the event of loss, lies with the former owners. For these lawsuits, the provision is made under “Tax, social security, labor and civil provision” against amounts receivable from former owners.

b) Contingent liabilities (possible risk of loss)

The Company and its subsidiaries are also party to lawsuits with a possible risk of loss (between 25% and 50%) as assessed by management under the advice of legal counsel. Based on this assessment, no provision has been made in the financial statements, as summarized below:

Labor and civil contingencies

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Civil lawsuits (i)				
Former owners – responsibility of selling party (a)	2,097	3,421	1,016,115	1,082,258
Management - DASA	49,252	38,269	386,112	210,692
Labor lawsuits				
Former owners – responsibility of selling party (a)	73	1,040	45,083	54,540
Management - DASA	132,853	102,952	299,972	204,603

(i) In the consolidated, the higher values under DASA Management refer to:

- indemnity lawsuit claiming the existence of acts of administrative misconduct and violation of principles and damages to the public coffers in the engagement of Hospital Maternidade Cristóvão da Gama by Instituto de Previdência de Santo André - IPSA, involving the former management of the hospital, in the total amount of R$ 338,581 at December 31, 2024 (R$ 310,909 at December 31, 2023), being a shared responsibility whereby 35% is under DASA responsibility (R$ 118,503 on December 31, 2024 and R$ 108,818 on December 31, 2023); and

- public civil action for administrative misconduct for alleged irregularities in the bidding process for the hiring of Cientifica Lab Produtos Laboratoriais e Sistemas Ltda. (“Científica Lab”) in the amount of R$ 52,040 on December 31, 2024 (R$ 49,054 on December 31, 2023).

(In thousands of reais, unless otherwise indicated)

Contingencies for tax and social security claims

Tax and social security claims correspond to (i) challenges for increases in rates (ii) calculation basis and (iii) unconstitutionality of charged.

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Tax and social security claims				
Former owners – responsibility of selling party (i)	15,931	15,279	423,729	408,679
Management - DASA	1,283,538	1,194,947	1,375,181	1,316,849

(i) In the consolidated, the higher values under DASA Management refer to:
- ISS lawsuits, regarding the location of clinical analysis services rendered, in the amount of R$ 619,913 on December 31, 2024 (R$ 593,973 on December 31, 2023);
- PIS/COFINS on revenue and imports in the amount of R$ 172,292 on December 31, 2024 (R$ 152,388 on December 31, 2023); and
- income tax and social contribution credits on net income in the amount of R$ 294,970 on December 31, 2024 (R$ 347,705 on December 31, 2023).

21 Share-based payment

Share-based payment plans are part of the DASA Group's incentive policy with the purpose of aligning the interests of the Company, its shareholders and beneficiaries, attracting talent, retaining executives and key employees, increasing the generation of sustainable results and reinforcing the long-term orientation of decision-making by the Company's executives and employees. Plans are managed by the Board of Directors, which may rely on a Committee to assist in this regard, and have, to the extent permitted by law and by the Company's bylaws, broad powers to take all necessary and appropriate measures for the management of these plans. Beneficiaries are chosen and elected by the Board of Directors, at is sole discretion.

The book value relating to the share-based payment is determined using the fair value in accordance with the market value of the shares on the grant date and is recognized on a straight-line basis in the statement of income for the year, during the vesting period, with a corresponding entry in shareholders' equity.

When options are exercised, the amounts received by the Company, net of any directly attributable transaction costs, are credited to share capital (nominal value) and to the goodwill reserve, if applicable.

The Company has the following share-based payment plans:

	Year of approval	Number of issued shares
2018 Plan	2018	4,663,274
2018 Plan	2019	5,215,000
2020 Plan	2020	7,181,250
2020 Plan	2021	6,413,500
2020 Plan	2022	6,506,500
2020 Plan	2023	8,843,375

(In thousands of reais, unless otherwise indicated)

The changes in outstanding options for the year ended December 31, 2024, including their respective weighted average exercise prices, are shown below:

Settlement in shares

	2022	2023	2023	2023
Life	3 years	2 years	3 years	3 years
Share price	23.45	12.37	12.35	12.37
Fair value	11.28	3.59	7.48	2.65
Strike price	27.00	20.54	9.15	33.80
Expected volatility	0.53	0.69	0.58	0.69
Risk-free rate	12.2%	9.4%	11%	9.5%
Maturity	2025	2025	2026	2026

Provision for share-based payment is as follows:

	Parent Company/ Consolidated
Balance at December 31, 2022	**567,429**
Stock option plan expense	61,572
Payments	(828)
Balance at December 31, 2023	**628,173**
Stock option plan expense	26,779
Reversal (a)	(76,351)
Balance at December 31, 2024	**578,601**

	12/31/2024	12/31/2023
Current liabilities	-	56,075
Non-current liabilities	-	16,962
Shareholders' equity	578,601	555,136
Total in balance sheet (share-based payment)	**578,601**	**628,173**

a) On September 11, 2024, the Supreme Court of Justice ruled on the nature of share-based payment plans. The Company, with the support of its legal advisors, reassessed the nature of its plans and concluded that the plans are of a commercial nature, reversing the provisions for labor charges recorded.

22 Shareholders' equity

a) Share capital

On December 31, 2024, the Company's paid-up and subscribed share capital of R$ 19,625,346 (R$ 18,032,489 on December 31, 2023), represented by 1,255,006,644 (752,799,844 common shares on December 31, 2023) common shares, nominative, book-entry and with no par value. The share issuance costs are recorded as a deduction from shareholders' equity (net of any tax benefit), in the amount of R$ 86,286.

The Company is authorized to increase capital up to the limit of 1,600,000,000 (one billion six hundred million) common shares, without need of prior amendments to the statute.

b) Share premium reserve

On November 27, 2017, the merger of Cromossomo Participações II S.A., which was a shareholder of DASA, was approved (downstream merger). As a result, the economic benefits arising from the tax amortization of goodwill were transferred to be used by the Company. Further details on this transaction, see Note 22 “Shareholders’ equity f) Premium reserve on downstream merger” of the financial statements as of December 31, 2017, issued on March 14, 2018.

c) Equity valuation adjustment and Other comprehensive income

Other comprehensive income represents the effects of translating balances to the presentation currency for foreign subsidiaries and of hyperinflationary accounting effects for the Argentine subsidiary.

Equity valuation adjustment is related to shareholder transactions for options of non-controlling shareholders of subsidiaries. Upon the merger of Ímpar into DASA in 2020, the amount of R$ 9,243,944 was recorded as an equity valuation adjustment, thus reducing Company’s shareholders’ equity. Further details available in Note 2 “Common control transactions” of the financial statements on December 31, 2020, issued on March 6, 2021.

d) Treasury shares

When shares issued by the Company are repurchased, the amount paid, including directly attributable costs, is recognized as a deduction from shareholders’ equity. If shares recognized as shareholders’ equity are repurchased, value of consideration paid, which includes directly attributable costs, is recognized in the shareholders’ equity.

On December 31, 2024, there are 5,361,750 shares held in treasury (5,751,757 on December 31, 2023), acquired at an average price of R$ 14.12 per share (R$ 14.13 on December 31, 2023), corresponding to R$ 79,136 (R$ 81,258 on December 31, 2023).

On August 12, 2022, a repurchase program of own shares was approved by the Board of Directors. The number of shares to be acquired in the buyback program was limited to 14,060,719 common shares, accounting for 19.57% of the shares outstanding in the market, on the approval date, following the limit set forth in Article 9 of CVM Resolution 77. The repurchase program ended on February 12, 2024. Under the repurchase program, 1,046,600 shares were purchased in the year ended December 31, 2023, totaling R$ 13,453. No shares were acquired in 2024.

e) Allocation of income for the year

According to the Company’s by-laws, net income for the year is allocated as follows: (i) 5% appropriated to a legal reserve, until it reaches 20% of subscribed share capital; and (ii) at least 25% of the remaining balance adjusted, pursuant to article 202 of Law 6404/76, for the payment of minimum mandatory dividends.

In 2023 and 2024, the Company had no profit available for allocation.

(In thousands of reais, unless otherwise indicated)

23 Net operating revenue

The operating revenue of the Company and its subsidiaries arises mainly from the provision of services from diagnostic and hospital activities, net of related taxes and variable consideration, such as commercial discounts and disallowances. Contracts with health plan operators include variable consideration and, therefore, the Company and its subsidiaries estimate the corresponding income taking into account contractual prices and historical disallowances. For information on PECLD and disallowances, see Note 7.

The contracts signed between the DASA Group and its customers are commercial by nature, as they are approved by the parties and generate rights for each of the parties, as well as the payment conditions identified.

The gross operating revenue by segment and its reconciliation with net operating revenue is presented below:

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Operating revenue per segment:				
Hospitals and oncology (BU1)	-	-	8,627,523	8,067,012
Diagnoses and care coordination (“BU2”)	6,112,324	5,630,149	7,655,141	7,282,700
Diagnoses - International Operations (BU2 Internacional)	-	-	516,946	207,544
	6,112,324	**5,630,149**	**16,799,610**	**15,557,256**
Deductions:				
Taxes on billing	(365,323)	(336,967)	(1,011,782)	(940,540)
Losses from variable consideration (disallowance)	(84,076)	(41,138)	(375,925)	(300,953)
Commercial discounts	(85,009)	(37,223)	(89,824)	(63,528)
Net operating income	**5,577,916**	**5,214,821**	**15,322,079**	**14,252,235**

Information by business segment (BU1, BU2 and BU2 Internacional) is presented in Note 28.

The DASA Group has the following concentration among its client portfolios, being that the largest five main customers are as follows:

	12/31/2024	12/31/2023
CLIENT A	13%	13%
CLIENT B	12%	11%
CLIENT C	10%	10%
CLIENT D	9%	7%
CLIENT E	4%	3%

(In thousands of reais, unless otherwise indicated)

24 Expenses by nature

The Company and its subsidiaries present the statement of income by function, and details by nature as follows:

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Personnel expenditures	(1,507,588)	(1,485,228)	(4,072,644)	(3,884,146)
Cost with material	(1,060,641)	(960,655)	(3,680,384)	(3,378,954)
Services and utilities	(1,776,347)	(1,662,881)	(4,142,754)	(3,891,089)
Depreciation and amortization	(773,545)	(801,784)	(1,366,818)	(1,296,304)
General expenditures	(60,618)	(47,876)	(353,667)	(352,356)
Provision for profit sharing and bonus	(110,607)	(22,271)	(184,027)	(19,303)
Share-based payment plan (Note 21)	(19,841)	(56,608)	(24,414)	(66,585)
Advertising and publicity	(42,003)	(52,772)	(72,658)	(86,013)
Transportation expenses	(96,840)	(66,658)	(114,334)	(72,948)
Taxes and rates	(3,833)	(6,149)	(14,574)	(18,896)
Expected losses from doubtful accounts	(3,233)	(9,342)	(40,173)	(1,188)
On lending of corporate expenses (Note 30.d)	379,084	353,908	-	-
Other	(72,417)	(69,493)	(249,108)	(272,751)
Total	**(5,148,429)**	**(4,887,809)**	**(14,315,555)**	**(13,340,533)**
Classified as:				
Costs of services rendered	(3,692,489)	(3,537,417)	(11,128,831)	(10,365,230)
General and administrative expenses	(1,455,940)	(1,350,392)	(3,186,724)	(2,975,303)
Total	**(5,148,429)**	**(4,887,809)**	**(14,315,555)**	**(13,340,533)**

25 Financial income (expenses)

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Financial income				
Interest	144,985	187,873	216,322	262,673
Derivative financial instruments	51,789	47,237	62,830	56,938
Exchange rate change and indexation credits	6,056	1,405	(27,870)	(24,956)
Other	776	43	2,954	2,164
	203,606	**236,558**	**254,236**	**296,819**
Financial expenses				
Interest on loans and debentures	(1,283,538)	(1,452,034)	(1,311,728)	(1,528,916)
Interest on right-of-use lease	(103,309)	(88,898)	(305,688)	(217,993)
Interest (a)	(53,489)	(20,337)	(71,375)	(44,225)
Derivative financial instruments	(368,990)	(54,338)	(368,990)	(55,338)
Indexation charges on payables for acquisition of subsidiaries	(7,800)	(20,458)	(144,180)	(149,660)
Exchange rate change and indexation charges	(51,928)	(42,284)	(58,278)	(100,436)
Interest charges on lawsuits	9,397	5,244	7,540	7,070
Intercompany financial income (expense) (b) (Note 30.d)	470,740	836,530	-	-
Other	(72,329)	(55,467)	(162,887)	(116,598)
	(1,461,246)	**(892,042)**	**(2,415,586)**	**(2,206,096)**
	(1,257,640)	**(655,484)**	**(2,161,350)**	**(1,909,277)**

(a) Other interest expenses include late payment interest, prepayment of receivables, among others.
(b) On July 1, 2024, the Parent Company discontinued the transfer of financial expenses to its subsidiaries.

Some amounts presented in the financial result on December 31, 2023, were reclassified for better comparability with the amounts presented in 2024.

26 Earnings (loss) per share

Basic earnings per share are calculated by dividing net profit (loss) attributable to Company's controlling shareholders by the weighted average number of outstanding common shares during the period.

Diluted earnings per share are calculated by adjusting the weighted average number of outstanding common shares, considering the conversion of all potential common shares that would provoke a dilution. The Company's dilution factor is the stock option plan (see Note 21).

A reconciliation of the numerators and denominators used to calculate earnings per share follows:

	Parent Company	
	12/31/2024	12/31/2023
Loss attributable to Company's controlling shareholders	**(1,198,990)**	**(1,166,016)**
Weighted average number of outstanding common shares (in thousands)	1,249,533	747,048
Basic loss per share - (in R$)	**(0.95955)**	**(1.56083)**
Loss attributable to Company's controlling shareholders	**(1,198,990)**	**(1,166,016)**
Weighted average number of common shares for diluted calculation (in thousands)	1,288,356	785,871
Diluted loss per share - (in R$)	**(0.93064)**	**(1.48372)**
Weighted average number of shares (in thousands)		
Weighted average number of shares for basic earnings per share	1,249,533	747,048
Dilution effect:		
Stock option plan	38,823	38,823
Weighted average number of shares for diluted earnings per share	1,288,356	785,871

27 Income tax and social contribution

Corporate income tax (IRPJ) and social contribution (CSLL) are calculated based on the rates of 25% and 9%, respectively, as defined by current legislation. Both taxes are calculated based on taxable income, i.e., the result for the year adjusted through tax additions and exclusions.

Provisions for IRPJ and CSLL comply with the accrual basis of accounting and are recognized in the statement of income, except when related to items recognized directly in shareholders' equity, which are recognized in the respective group of accounts.

Deferred tax assets and liabilities are recognized to reflect future tax effects attributable to temporary differences between the calculation basis and the respective book values. For disclosure purposes, the deferred tax asset was offset against the deferred tax liability of the same taxable entity and the same tax authority.

In compliance with IFRIC23/ICPC22 ("Uncertainty over Income Tax Treatment"), management, with the support of external advisors, periodically assesses whether the positions taken in relation to situations in which the applicable tax regulations require interpretations are appropriate. When applicable, a provision is formed based on estimated amounts of payment to the tax authorities. For the year ended, the tax treatment adopted by the Company and its subsidiaries and corresponding provisions is considered by management to be sufficient.

(In thousands of reais, unless otherwise indicated)

The reconciliation of the statutory IRPJ and CSLL rates to the respective effective rate is presented below:

	Parent Company		Consolidated	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Loss before income tax and social contribution	(1,347,331)	(1,170,150)	(1,067,357)	(995,954)
Statutory tax rate - %	34%	34%	34%	34%
Income tax and social contribution:				
At nominal rate	458,093	397,851	362,901	338,625
Effect of tax rates in foreign jurisdictions (30%)	-	-	(6,905)	(25,437)
Permanent differences				
Equity in results of subsidiaries	(184,429)	(284,773)	-	-
Benefit from interest on own capital	-	(915)	-	5,625
Non-deductible expenses (i)	(21,306)	(15,549)	(54,489)	(192,266)
Other adjustments				
Presumed tax regime (ii)	-	-	5,889	(483)
Tax loss carryforwards (iii)	(89,266)	(92,480)	(298,259)	(260,315)
Reprocessing of IRPJ and CSLL calculation (iv)	21,758	-	(97,566)	-
Other (v)	(36,509)	-	(40,143)	435
IRPJ and CSLL in the statement of income	**148,341**	**4,134**	**(128,572)**	**(133,816)**
Current	(3,530)	-	(342,592)	(131,888)
Deferred	151,871	4,134	214,020	(1,928)
Total	**148,341**	**4,134**	**(128,572)**	**(133,816)**
Effective rate of IRPJ and CSLL (iv)	-11.0%	-0.4%	12.0%	13.4%

(i) Nondeductible expenses, such as: expenses with fines, donations, gifts and others.
(ii) Brazilian tax legislation allows the companies that earned gross income of up to R$ 78 million in the previous year, to use a simplified presumed tax regime. Some of the Company's subsidiaries adopt this tax regime, according to which the IRPJ and CSLL calculation basis is calculated applying a presumed profit rate equivalent to 8% of the adjusted operational income. The reconciling item is the difference between the presumed tax regime expense and the statutory nominal tax expense.
(iii) Deferred IRPJ and CSLL on carryforward tax losses not recorded as assets in the year.
(iv) In the fourth quarter of 2024, management hired external tax experts to review the processes related to the preparation of income tax and social contribution calculations and the corporate expenses transfer.
(v) Mainly refers to the write-off of balances recorded as judicial deposits, relating to discussions on income tax issues, released in favor of the Federal Government.
(vi) The effective tax rate on profits is calculated as the ratio between IRPJ and CSLL expenses (current and deferred) and profit (loss) before IRPJ and CSLL. This is a different percentage from the nominal rate, since taxable profit is calculated through adjustments provided for in tax legislation in determining accounting profit (loss).

(In thousands of reais, unless otherwise indicated)

The balances and changes in deferred IRPJ and CSLL balances is shown below:

	Parent Company			
	Balance at 12/31/2023	Changes reflected in statement of income	Changes reflected in equity	Balance at 12/31/2024
Tax loss carryforwards	1,085,960	-	(2,870)	1,083,090
Provision for estimated losses on doubtful accounts and provision for disallowances	17,137	18,442	-	35,579
Sundry provision for specialized medical services	33,387	(24,481)	-	8,906
Provision for stock option plan	115,128	-	-	115,128
Provision for variable remuneration, disputes and overtime	5,193	31,705	-	36,898
CPC 06 (R2)/IFRS 16 – Lease	12,846	21,049	-	33,895
Provision for obsolescence	200	2,143	-	2,343
Adjustment to present value	3,459	(2,626)	-	833
Provision for legal disputes	31,743	(20,891)	-	10,852
Adjustment of useful lives of property and equipment	21,738	3,271	-	25,009
Difference between fair value and book value in subsidiaries acquisition	21,090	37,574	-	58,664
Financial instruments (swap)	-	102,144	-	102,144
Goodwill - tax amortization	(417,599)	5,464	-	(412,135)
Other	5,748	(21,923)	10	(16,165)
Deferred income tax and social contribution	**936,030**	**151,871**	**(2,860)**	**1,085,041**
Deferred tax assets	936,030			1,085,055
Deferred tax liabilities	-			(14)

	Parent Company			
	Balance at 12/31/2022	Changes reflected in statement of income	Changes reflected in equity	Balance at 12/31/2023
Tax loss carryforwards	1,085,960	-	-	1,085,960
Provision for estimated losses on doubtful accounts (PECLD) and provision for disallowances	65,596	(48,459)	-	17,137
Sundry provision for specialized medical services	(10,702)	44,089	-	33,387
Provision for stock option plan	96,991	18,137	-	115,128
Provision for variable remuneration, disputes and overtime	20,626	(15,433)	-	5,193
CPC 06 (R2)/IFRS 16 – Lease	19,698	(6,852)	-	12,846
Provision for obsolescence	4,277	(4,077)	-	200
Adjustment to present value	3,603	(144)	-	3,459
Provision for legal disputes	27,878	3,865	-	31,743
Adjustment of useful lives of property and equipment	19,846	1,892	-	21,738
Difference between fair value and book value in subsidiaries acquisition	(218)	21,308	-	21,090
Goodwill - tax amortization	(398,745)	(18,854)	-	(417,599)
Other	(2,905)	8,662	(9)	5,748
Deferred income tax and social contribution	**931,905**	**4,134**	**(9)**	**936,030**
Deferred tax assets	931,905			936,030

(In thousands of reais, unless otherwise indicated)

	Consolidated			
	Balance at 12/31/2023	Changes reflected in statement of income	Changes reflected in equity	Balance at 12/31/2024
Tax loss carryforwards	1,233,952	(1,857)	-	1,232,095
Provision for estimated losses on doubtful accounts and provision for disallowances	115,414	67,104	-	182,518
Sundry provision and for specialized medical services	79,108	(62,458)	-	16,650
Provision for variable remuneration, disputes and overtime	17,730	52,207	-	69,937
Provision for stock option plan	115,128	-	-	115,128
CPC 06 (R2)/IFRS 16 – Lease	53,472	22,816	-	76,288
Provision for ISS on income to be billed	10,685	1,301	-	11,986
Provision for obsolescence	2,051	292	-	2,343
Adjustment to present value	2,054	(2,475)	-	(421)
Equity valuation adjustment	22,575	(25,589)	-	(3,014)
Provision for legal disputes	28,596	2,263	-	30,859
Adjustment of useful lives of property and equipment	26,749	818	-	27,567
Difference between fair value and book value in subsidiaries acquisition	26,491	41,324	-	67,815
Goodwill - tax amortization	(418,135)	763	-	(417,372)
Financial instruments (swap)	-	104,068	-	104,068
Other	(43,018)	13,443	(16,560)	(46,135)
Deferred income tax and social contribution	**1,272,852**	**214,020**	**(16,560)**	**1,470,312**
Deferred tax assets	1,286,050			1,491,859
Deferred tax liabilities	(13,198)			(21,547)

	Consolidated			
	Balance at 12/31/2022	Changes reflected in statement of income	Changes reflected in equity	Balance at 12/31/2023
Tax loss carryforwards	1,265,837	(31,885)	-	1,233,952
Provision for estimated losses on doubtful accounts and provision for disallowances	72,466	42,948	-	115,414
Sundry provision and for specialized medical services	1,716	77,392	-	79,108
Provision for variable remuneration, disputes and overtime	59,472	(41,742)	-	17,730
Provision for stock option plan	116,934	(1,806)	-	115,128
CPC 06 (R2)/IFRS 16 – Lease	19,538	33,934	-	53,472
Provision for ISS on income to be billed	-	10,685	-	10,685
Provision for obsolescence	4,282	(2,231)	-	2,051
Adjustment to present value	3,603	(1,549)	-	2,054
Equity valuation adjustment	19,679	2,896	-	22,575
Provision for legal disputes	29,442	(846)	-	28,596
Adjustment of useful lives of property and equipment	19,846	6,903	-	26,749
Difference between fair value and book value in subsidiaries acquisition	(1,257)	27.748	-	26,491
Goodwill - tax amortization	(399,376)	(18,759)	-	(418,135)
Other	51,846	(105,616)	10,752	(43,018)
Deferred income tax and social contribution	**1,264,028**	**(1,928)**	**10,752**	**1,272,852**
Deferred tax assets	1,288,738			1,286,050
Deferred tax liabilities	(24,710)			(13,198)

A deferred tax asset is recognized for tax carryforward losses and other deductible temporary differences, to the extent that is probable that future taxable income will be available for offset, by corporate entity based on business plans of the Company and its subsidiaries. Tax losses have no statute of limitations, though offsetting is limited by law to 30% of taxable profits.

(In thousands of reais, unless otherwise indicated)

Pursuant to CPC 32/IAS 12 – Income Taxes, the Company and its subsidiaries record deferred tax assets and liabilities on temporary differences and tax losses on the expectation of future taxable income. This requires considerable judgment by the management in determining future taxable profits, based on internal assumptions and forecast economic scenarios that are subject to change.

The deferred tax assets on tax losses are expected to be realized as follows:

	Parent Company	Consolidated
2027	18,547	21,098
2028	42,216	48,024
2029	69,237	78,762
2030	107,586	122,387
2031	135,480	154,119
2032–2035	710,024	807,705
	1,083,090	**1,232,095**

Projections for the realization of deferred tax assets are reviewed annually and approved by management. At December 31, 2024, no indicators of non-recovery of deferred taxes had been identified.

Reform of taxes on consumption

On December 20, 2023, the National Congress enacted Constitutional Amendment (EC) 132, which addresses the Tax Reform on Consumption.

In general terms, the new tax model will replace the current taxes on consumption (PIS, COFINS, ISS and ICMS) with two taxes: Tax on Goods and Services (IBS) and Contribution on Goods and Services (CBS). Moreover, there will be a new tax on goods harmful to health and the environment, called the Selective Tax (IS), which will replace the Tax on Industrial Products (IPI).

On January 16, 2025, Complementary Law 214/25 was sanctioned, as the result of the conversion of Complementary Law (PLP) 68/24, which regulates important aspects of the Tax Reform, such as: levy and non-levy, tax credits, industries with specific treatments, operations with rate reductions, among others, without yet defining the nominal rate of the new taxes. For the healthcare industry, a positive indicator is the 60% reduction in the nominal tax rate for services and the 60% or 100% reduction for several medicines and supplies.

Other relevant aspects of the Tax Reform will have to be regulated during the year 2025, since in 2026 to 2032 companies will be in a transition period with the existence of two consumption tax regimes: old (PIS, COFINS, ISS, ICMS and IPI) and new (IBS, CBS and IS).

The impact of the Tax Reform will only be fully known when the process of regulating the outstanding topics is completed. Therefore, there is no effect to be recognized in the financial statements for the year ended December 31, 2024.

International tax reform - Pillar two model rules

In line with the Organization for Economic Cooperation and Development (OECD) initiative to curb international tax competition and discourage abusive tax planning aimed at drastically reducing the tax burden (known as "Pillar 2"), Provisional Measure 1262/24 and RFB Normative Instruction 2228/24 were published on October 3, 2024.

Both rules aim to ensure that the profits of multinational groups are taxed at a minimum effective rate of 15%, regardless of where they are generated, and cover groups that have earned annual income of at least EUR 750 million in the consolidated financial statements of the final investing entity in at least two of the four tax years.

The Company is assessing the potential impacts and will consider them, if applicable, in the relevant periods.

28 Information by business segment

For the purposes of analysis and decision making by Management, the DASA Group's operations are managed in three strategic divisions, which are its reportable segments: (i) outpatient care services and care coordination; (ii) hospitals and oncology - through Ímpar and its subsidiaries and (iii) International operations - auxiliary support services located in Argentina. The operating segment is reported consistently with management reports used by the chief operating decision maker (Chief Executive Officer) to assess segment performance and resource allocation. The Chief Executive Officer of DASA Group analyzes the internal management reports of each division at least quarterly. The following summary describes the operations of each segment:

Segments	Operations	Geographic region
Hospitals and oncology (BU1)	Medical and hospital services	Brazil
Diagnoses and care coordination ("BU2")	Diagnosis and health management	Brazil
Diagnósticos Internacional (BU2 Internacional)	Diagnosis	South America (Argentina)

The segment performance was assessed based on net operating revenue, net profit (loss), and employed capital (total assets less current and non-current liabilities) in each segment.

(In thousands of reais, unless otherwise indicated)

Segment reporting is presented below:

	Hospitals and oncology (BU1)		Diagnoses and care coordination ("BU2")		Diagnoses - International Operations ("BU2")		Total profit (loss) - from continued operations		Discontinued operations (i)	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023	12/31/2024	12/31/2023	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Net operating income	7,816,498	7,326,929	7,101,366	6,813,327	508,626	197,141	15,322,079	14,252,234	9,877	8,506
Cost of services	(6,037,581)	(5,583,938)	(4,845,455)	(4,727,572)	(350,206)	(138,883)	(11,128,831)	(10,365,230)	(4,420)	(14,162)
Gross income	**1,778,917**	**1,742,991**	**2,255,911**	**2,085,755**	**158,420**	**58,258**	**4,193,248**	**3,887,004**	**5,457**	**(5,656)**
Operating income (expenses), net	(1,241,650)	(1,181,760)	(1,789,683)	(1,757,512)	(67,922)	(34,410)	(3,099,255)	(2,973,682)	(6,287)	(21,508)
Profit before financial result and taxes	**537,267**	**561,231**	**466,228**	**328,243**	**90,498**	**23,848**	**1,093,993**	**913,322**	**(830)**	**(27,164)**
Financial income (expenses), net	(756,421)	(1,033,327)	(1,371,668)	(835,935)	(33,261)	(40,015)	(2,161,350)	(1,909,277)	2,057	(652)
Income tax and social contribution	(199,885)	(63,180)	96,714	(58,948)	(25,401)	(11,687)	(128,572)	(133,815)	751	(413)
Net profit (loss) by segment	**(419,039)**	**(535,276)**	**(808,726)**	**(566,640)**	**31,836**	**(27,854)**	**(1,195,929)**	**(1,129,770)**	**1,978**	**(28,229)**

Consolidated

	Hospitals and oncology (BU1)		Diagnoses and care coordination ("BU2")		Diagnoses - International Operations ("BU2")		Discontinued operations		Total	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023	12/31/2024	12/31/2023	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Total assets	14,785,901	14,221,881	21,237,972	21,516,756	420,414	146,824	3,422	18,848	26,458,471	26,213,200
Total current and non-current liabilities	6,631,167	6,459,563	12,967,162	13,447,517	120,718	68,046	-	2,703	18,522,823	18,879,381

(i) Profit (loss) from discontinued operations excluded from the Company's profit (loss).

(ii) Amounts net of elimination between segments

(In thousands of reais, unless otherwise indicated)

29 Risks and financial instruments

a) Risk management

The Company's management believes that the main risk factors to which is exposed are market risk, exchange rate risk, interest rate risk, credit risk and liquidity risk. Risks are inherent to its activities and are managed through internal policies and monitored through periodic reports.

a.1) Liquidity risk

DASA group manages liquidity risk by maintaining sufficient reserves, bank credit facilities and credit facilities to raise loans as required, through continuous monitoring of expected and actual cash flows and through combination of financial assets and liabilities' maturity profiles by allocating:

a) Short-term cash management - Management of liquid assets and credit facilities to cover immediate needs.

b) Long-term cash management - Ongoing process to guarantee long-term funds, by analyzing the cash budget on a monthly basis, updating the budgeted assumptions according to the needs of the business, and comparing the actual versus budgeted amounts.

c) Maintenance of a minimum cash – Short term cash generation to meet urgent needs. The Company adopts a policy that the cash balance must be sufficient to cover the five worst daily outflows of the month, without considering receipts.

d) Exposure limits and risk mitigators - The treasury department has short-term lines for cash investments with immediate liquidity and working capital facilities sufficient to guarantee at least the amount equal to the five largest consecutive days of cash disbursements in the last 12 months.

For medium-term and long-term facilities, the treasury department credit facilities are compatible with DASA Group's strategic planning, assuring the availability of funds to meet the expected cash outflows.

The following table shows the maturities of the consolidated non-current financial liabilities that are contracted (undiscounted) and, therefore, may not agree directly to the balance sheets:

12/31/2024

Operation	01−02 years	02−03 years	03−04 years	>04 years	Total
Derivative financial instruments	2,541	3,687	4,628	312,911	323,767
Suppliers	44,574	-	-	-	44,574
Loans and financing	7,399	-	-	-	7,399
Debentures	3,572,754	3,195,917	2,144,181	4,209,956	13,122,808
Leases	151,148	312,163	999,685	789,998	2,252,994
Payable - acquisition of subsidiaries	142,488	619,318	47,897	18,014	827,717
	3,920,904	**4,131,085**	**3,196,391**	**5,330,879**	**16,579,259**

(In thousands of reais, unless otherwise indicated)

12/31/2023

Operation	01–02 years	02–03 years	03–04 years	>04 years	Total
Derivative financial instruments	25,106	-	-	-	25,106
Suppliers	46,743	-	-	-	46,743
Loans and financing	37,628	15,514	-	-	53,142
Debentures	1,961,745	3,545,210	7,078,439	-	12,585,393
Leases	175,940	359,092	350,704	1,378,856	2,264,593
Share-based payment	21,954	-	-	-	21,954
Payable - acquisition of subsidiaries	183,720	578,082	-	-	761,802
	2,452,836	**4,497,898**	**7,429,143**	**1,378,856**	**15,758,733**

a.2) Foreign exchange risk

The operations of the Company and its subsidiaries are carried out in Brazil. Therefore, the reference currency for currency risk management is the Brazilian Real (the Company's functional currency), except for the subsidiary Diagnóstico Maipú por Imágenes S.A. ("Maipú") which operates in Argentina and has the Argentine Peso as its reference currency. Currency risk management seeks to neutralize foreign exchange exposures by addressing the risks of the Company and its subsidiaries to exchange rate changes.

If required, the Company and its subsidiaries use foreign exchange hedge instruments (mainly between the Real and the US Dollar) available in the financial market to hedge their assets, liabilities, receipts and disbursements in foreign currency seeking to reduce the effects of exchange rate changes on its results and cash flow in Reais, within the exposure limits of the policy. When applicable, these foreign exchange hedge instruments have amounts, terms and indexes substantially equivalent to the assets, liabilities, receipts and disbursements in foreign currency to which they are linked.

In 2022, the subsidiary Ímpar contracted loans in foreign currency (US dollars) for which derivative financial instruments were contracted to hedge against exchange rate fluctuations. The loan was settled at maturity on October 4, 2024.

On December 31, 2024, the Company and its subsidiaries did not have any open positions in foreign exchange hedging instruments, since, on this date, they have no foreign currency exposures.

a.3) Interest rate risk

The Company and its subsidiaries adopt policies for raising and investing financial resources and minimizing the cost of capital. Cash equivalents and interest earning bank deposits (Notes 5 and 6) are held mainly in DI-linked operations and funding is mainly from debentures (Note 16). The Company and its subsidiaries seek to maintain most of their financial assets and liabilities at floating interest rates and, when necessary, enter into derivative financial instruments to achieve this objective.

To monitor the sensitivity of cash and cash equivalents, interest earning bank deposits and debentures to interest rate exposure, the Company defined different scenarios with stress factors of 25% and 50%. For each scenario, the Financial income (expense) was calculated, considering the flow of maturities for each contract scheduled for 2025, excluding taxes effects. Judicial deposits held in escrow for lawsuits for acquired companies in the amount of R$ 7,165 on December 31, 2024, were not considered in this projection.

(In thousands of reais, unless otherwise indicated)

Operation	Balance at 12/31/2024	Note	Risk	Scenario I - Probable	Scenario II 25% increase	Scenario III 50% increase
Cash and cash equivalents/interest earning bank deposits	1,895,329	5|6	CDI	253,971	317,463	380,956
Profitability of interest earning bank deposits - %				98.17%	98.17%	98.17%
Cash and cash equivalents applied – (% vs total cash)				91.00%	91.00%	91.00%
Debentures	(10,387,001)	16	CDI	(1,762,310)	(2,158,484)	(2,554,657)
Debenture spread - %				1.71%	1.71%	1.71%
Derivative instruments – interest rate hedge	(324,908)			22,958	(114,136)	(243,106)
Net exposure – financial expense	**(8,816,580)**		**CDI**	**(1,485,381)**	**(1,955,157)**	**(2,416,807)**
Rate subject to change			CDI	15.00%	18.75%	22.50%

The Company has entered into derivative financial instruments to convert the National Amplified Consumer Price Index ("IPCA") indicator of certain debentures into floating CDI rates, as follows:

Interest rate swap (IPCA to CDI)	Nominal value	Balance 12/31/2024	Original indexes	Swap	Start	Maturity	Unrealized gains (losses) from derivative instruments on 12/31/2024
XP	419,184	469,529	IPCA+6.60%	CDI+1.05%	05/24/2023	10/15/2029	(56,814)
Itaú	247,482	277,287	IPCA+6.75%	CDI+1.22%	11/11/2022	10/15/2032	(2,857)
XP	124,430	134,120	IPCA+7.34%	CDI+1.96%	02/01/2024	01/15/2031	(15,287)
XP	210,090	226,718	IPCA+7.61%	CDI+2.13%	02/01/2024	01/16/2034	(32,978)
							(107,936)

The Company has entered into derivative financial instrument contracts to convert the fixed rates of certain debentures into the floating CDI rates, as follows:

Interest rate swap (fixed CDI rate)	Nominal value	Balance at 12/31/2024	Original indexes	Swap	Start	Maturity	Unrealized gains (losses) from derivative instruments on 12/31/2024
XP	551,248	582,020	Fixed rate 12.30%	CDI+1.97%	02/01/2024	01/15/2029	(87,694)
Itaú	690,427	730,637	Fixed rate 12.85%	CDI+2.36%	02/02/2024	01/15/2031	(129,280)
							(216,974)

The balances of derivative financial instrument contracts are presented below:

Consolidated	12/31/2024			12/31/2023		
Swap	Current	Non-current	Total	Current	Non-current	Total
Assets	-	-	-	-	-	-
Liabilities	(1,141)	(323,768)	(324,909)	(885)	(23,601)	(24,486)
	(1,141)	**(323,768)**	**(324,909)**	**(885)**	**(23,601)**	**(24,486)**

The derivative financial instruments presented above have the same terms and payment flows as the underlying debts for which they were contracted to convert the original indexes to floating CDI rates.

a.4) Credit risk

The financial instruments for which the Company and its subsidiaries carry credit risks from the counterparty are represented mainly by cash and cash equivalents (cash and banks) and interest earning bank deposits (Notes 5 and 6), hedging instruments and other assets and accounts receivable (Note 7).

a.4.1) Counterparty credit risk

This risk arises from the potential inability of counterparties to fulfill their financial obligations to the Company or its subsidiaries due to insolvency, in addition to the risk related to the assets that make up some exposure. The Company and its subsidiaries regularly carry out credit analysis of the institutions in which they hold cash, interest earning bank deposits and hedge instruments through various methodologies that assess liquidity, solvency, leveraging, quality of the portfolio, among others, prioritizing security and solidity. The volume of cash and cash equivalents, interest earning bank deposits, hedging instruments and other assets are subject to maximum limits per institution, with minimum diversification of counterparties. Institutions must have a minimum investment grade rating from specialized credit rating agencies.

a.4.2) Client credit risk

Client credit risk is the risk of a counterparty not complying with its contractual obligations, thus causing the Company and its subsidiaries to incur financial losses. The credit risk in trade accounts receivable is disclosed in Note 7 and the concentration in the client portfolio is disclosed in Note 23.

a.5) Climatic risks

Climate risk arise in the normal course of business. Based on the classifications used by the Task-Force on Climate-Related Financial Disclosures, there are two primary sources of financial risks related to climate change: physical and transitional.

Transitional and physical risks are when climate changes could adversely affect the business, condition and results of operations. Physical risks resulting from climate change can be caused by events (acute) or long-term (chronic) climate change: (i) acute physical risks include extreme weather events such as droughts, hurricanes or floods; and (ii) chronic physical risks include changes in precipitation patterns and extreme variability in weather patterns, rising average temperatures, chronic heat waves, or rising sea levels.

Transitional risks refer to actions taken to meet mitigation and adaptation requirements related to climate change, and fall into several categories such as: (i) market risk can occur through changes in supply and demand for certain commodities, products and services, as climate-related risks and opportunities are increasingly taken into account; (ii) technological risk arises from improvements or innovations to support the transition to a low-carbon, energy-efficient economic system that can have a significant impact on businesses as new technology displaces old systems and disrupts some parts of the existing economic system; and (iii) policy actions generally which fall into two categories – those that attempt to constrain actions that contribute to the adverse effects of climate change and those that seek to promote adaptation to climate change. The associated risk and financial impact of policy changes depend on the nature and timing which occur these changes.

(In thousands of reais, unless otherwise indicated)

The Company's business, operations and results may be affected by transitional risks, such as, but not limited to: (i) the scarcity of inputs and raw materials can cause increased costs, increased spending on research and development and restrictions or changes in production activities; (ii) expenditure on transitioning to more sustainable technologies due to changing technology needs for new service developments or adaptation of existing services; (iii) regulations associated with carbon pricing and greenhouse gas emission standards can cause restrictions and increase the cost of services; (iv) increase in the price of services and/or reduction in the profit margin; (v) increase in costs associated with adaptations in production as a result of restrictions in legislation on the use of water resources; (vi) difficulties in accessing assets or shortages of raw materials; (vii) loss of income due to the withdrawal of less sustainable services from the portfolio; and (viii) reduced demand for services due to changes in client preferences.

Management did not identify any accounting impact or need for additional disclosure.

b) Capital management

Management monitors the financial leverage ratio, which corresponds to consolidated net debt divided by capitalization (consolidated net debt plus shareholders' equity, excluding non-controlling interests in subsidiaries). Net debt corresponds to short- and long-term loans, financing and debentures, positive and negative balances of derivative financial instruments, less cash and cash equivalents and interest earning bank deposits.

The financial leverage ratios can be summarized as follows:

	12/31/2024	12/31/2023
Total gross debt	10,397,009	10,651,437
Total cash and cash equivalents and interest earning bank deposits	(1,895,329)	(1,689,009)
Net balance of derivative transactions	324,908	18,826
Net debt	**8,826,588**	**8,981,254**
Shareholders' equity	7,926,007	7,330,427
Total capitalization	16,752,595	16,311,681
Leverage ratio	**52.7%**	**55.1%**

c) Financial instruments

Financial assets

The Company and its subsidiaries classify, and measure financial assets as follows:
• Amortized cost: financial assets held for the purpose of receiving contractual cash flows, solely principal and interest. Income earned and exchange rate changes are recorded in the statement of income and the balances are stated at amortized cost using the effective interest method.
• Measured at fair value through profit or loss: financial assets that were not classified as amortized cost or measured at fair value through other comprehensive income. Balances are stated at fair value, and not only income earned and exchange rate changes but also changes in fair value are recorded in statement of income. Financial assets measured at fair value through profit or loss include derivative financial instruments.
• Measured at fair value through other comprehensive income: the DASA Group has not classified any financial asset as measured at fair value through other comprehensive income.

Financial liabilities

Financial liabilities include trade payables, other accounts payable, loans and financing, debentures, leases payable and derivative financial instruments used as hedge instruments.
• Financial liabilities measured at amortized cost are stated at the initial transaction value plus interest and net of amortization and transaction costs. Interest is recognized in the statement of income using the effective interest rate method.
• Financial liabilities measured at fair value through profit or loss are stated at fair value and both interest and exchange rate changes and fair value changes are recorded in the statement of income. Financial liabilities measured at fair value through profit or loss include derivative financial instruments.

Transaction costs, incurred and directly attributable to the fundraising of financing or the issuance of debt securities, as well as the premiums on the issuance of debentures and other debt instruments, are appropriated to the respective instrument and amortized in profit (loss), considering its term, using the effective interest rate method.

c.1) Fair values hierarchy for financial instruments

When available, the Company and its subsidiaries measure the fair value of security using the price quoted on an active market for such securities. Otherwise, the fair value was determined by means of calculation methods usually applied for marking to market, which consist in calculating future cash flows associated to each contracted instrument and bringing them to the present value by the market rates on base date of financial statements. In some cases, where there is no active market for the financial instrument, and quotations provided by the counterparties of the operations may be used. Market data interpretation for the purpose of choosing methodologies requires considerable judgment and establishment of estimates to get to an amount considered appropriate for each situation. Accordingly, presented estimates may not necessarily indicate amounts that may be obtained in the current market.

Financial instruments are classified according to the following categories:

- Level 1 - Prices quoted (not adjusted) in active markets for identical assets and liabilities.
- Level 2 – Inputs, in addition to quoted prices, included in Level 1 that is observable for the asset or liability, either directly (prices) or indirectly (derived from prices).
- Level 3 - Assumptions, for assets or liabilities, which are not based on observable market data (non-observable data).

The fair values and book balances of financial assets and liabilities, including derivative financial instruments, and the fair value hierarchy for each class of financial instruments are presented below:

(In thousands of reais, unless otherwise indicated)

Parent Company

December 31, 2024		Book value			
	Note	Measured at fair value through profit or loss	Amortized cost	Level	Fair value
Financial assets					
Cash and cash equivalents	5	-	28,583	-	28,583
Interest earning bank deposits	6	-	88,898	-	88,898
Trade accounts receivable	7	-	1,264,740	-	1,264,740
Repurchase and resale agreements and CDBs	5	-	432,680	-	432,680
Restricted financial investments	19	6,448	-	Level 2	6,448
Total		**439,128**	**1,382,221**		**1,821,349**
Financial liabilities					
Debentures	16	-	10,387,001	-	10,695,150
Suppliers	14	-	643,672	-	643,672
Payable - acquisition of subsidiaries	19	-	76,557	-	76,557
Lease liabilities	13	-	852,898	-	852,898
Contingent consideration	19	13,676	-	Level 3	13,676
Derivative financial instruments		324,908	-	Level 2	324,908
Total		**338,584**	**11,960,128**		**12,606,861**

Consolidated

December 31, 2024		Book value			
	Note	Measured at fair value through profit or loss	Amortized cost	Level	Fair value
Financial assets					
Cash and cash equivalents	5	-	164,233	-	164,233
Interest earning bank deposits	6	-	152,567	-	152,567
Trade accounts receivable	7	-	4,987,095	-	4,987,095
Repurchase and resale agreements and CDBs	5	-	1,578,529	-	1,578,529
Restricted financial investments	19	7,165	-	Level 2	7,165
Total		**1,585,694**	**5,303,895**		**6,889,589**
Financial liabilities					
Loans and financing	15	-	10,008	-	8,214
Debentures	16	-	10,387,001	-	10,695,150
Suppliers	14	-	1,482,847	-	1,482,847
Payable - acquisition of subsidiaries	19	-	995,191	-	995,191
Lease liabilities	13	-	2,596,378	-	2,596,378
Contingent consideration	19	72,819	-	Level 3	72,819
Derivative financial instruments		324,908	-	Level 2	324,908
Total		**397,727**	**15,471,425**		**16,175,507**

(In thousands of reais, unless otherwise indicated)

Parent Company

December 31, 2023		Book value			
	Note	Measured at fair value through profit or loss	Amortized cost	Level	Fair value
Financial assets					
Cash and cash equivalents	5	-	116,423	-	116,423
Interest earning bank deposits	6	-	79,561	-	79,561
Trade accounts receivable	7	-	1,013,051	-	1,013,051
Repurchase and resale agreements and CDBs	5	-	405,017	-	405,017
Restricted financial investments	19	6,475	-	Level 2	6,475
Total		**411,492**	**1,209,035**		**1,620,527**
Financial liabilities					
Loans and financing	15	-	11,958	-	11,838
Debentures	16	-	10,258,035	-	10,636,064
Suppliers	14	-	675,540	-	675,540
Payable - acquisition of subsidiaries	19	-	137,849	-	137,849
Lease liabilities	13	-	928,001	-	928,001
Contingent consideration	19	8,557	-	Level 3	8,557
Derivative financial instruments		24,486	-	Level 2	24,486
Total		**33,043**	**12,011,383**		**12,422,335**

Consolidated

December 31, 2023		Book value			
	Note	Measured at fair value through profit or loss	Amortized cost	Level	Fair value
Financial assets					
Cash and cash equivalents	5	-	438,908	-	438,908
Interest earning bank deposits	6	-	103,815	-	103,815
Trade accounts receivable	7	-	3,992,580	-	3,992,580
Repurchase and resale agreements and CDBs	5	-	1,146,286	-	1,146,286
Restricted financial investments	19	6,605	-	Level 2	6,605
Derivative financial instruments		7,165	-	Level 2	7,165
Total		**1,160,056**	**4,535,303**		**5,695,359**
Financial liabilities					
Loans and financing	15	-	192,270	-	144,914
Debentures	16	-	10,459,167	-	10,838,689
Suppliers	14	-	1,584,985	-	1,584,985
Payable - acquisition of subsidiaries	19	-	1,199,248	-	1,199,248
Lease liabilities	13	-	2,643,191	-	2,643,191
Contingent consideration	19	67,700	-	Level 3	67,700
Derivative financial instruments		25,991	-	Level 2	25,991
Total		**93,691**	**16,078,861**	**-**	**16,504,718**

(In thousands of reais, unless otherwise indicated)

30 Related parties

The Company's operations with related parties, were as follows:

a) Provision of services between the Company and its subsidiaries

	Current assets - Trade accounts receivable		Current liabilities - Other accounts payable		Net operating-income		Costs of services rendered	
	12/31/2024	12/31/2023	12/31/2024	12/31/2023	12/31/2024	12/31/2023	12/31/2024	12/31/2023
Científicalab Produtos Laboratoriais e Sistemas Ltda.	17,680	10,962	-	-	23,906	13,061	26	103
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	-	-	-	1,314	-	-	-	784
CPClin - Centro de Pesquisas Clínicas Ltda.	68	68	-	-	130	383	-	-
DASA Real Estate Empreendimentos Imobiliários Ltda. (a)	-	-	-	-	-	-	749	773
Genera Serviços Laboratoriais Ltda.	-	-	1,205	-	-	-	6,560	-
Genia - MOL	130	130	-	-	-	-	-	-
Genia Argentina S.A.	3,040	715	-	-	2,325	715	-	-
Genia Chile S.A.	253	79	-	-	174	79	-	-
Genia Colômbia S.A.	14	11	-	-	3	12	-	-
Ímpar Serviços Hospitalares S.A.	13,056	9,348	-	-	86,658	79,080	-	-
Instituto de Hematologia de S.J.R. Preto Ltda.	80	205	-	-	246	495	-	-
Itulab Laboratório de Análises Clínicas Ltda.	1,580	378	-	-	2,459	377	-	-
Laboratório Bioclínico MS Ltda.	3,608	3,328	-	-	1,574	1,040	-	-
Laboratório Chromatox Ltda.	-	-	-	2	-	-	-	-
Laboratório de Anatomia Patológica e Citopatologia São Camilo Ltda.	454	175	-	-	364	175	-	-
Laboratório Deliberato de Análises Clínicas Ltda.	-	2,874	-	-	2,685	1,744	-	-
Laboratório Exame de Análises Clínicas Ltda.	2,043	1,658	-	-	2,704	4,861	-	-
Laboratório Médico Santa Luzia S.A.	-	91	-	-	-	1,841	-	1
Laboratório Padrão de Análises Clínicas Ltda.	487	442	-	-	288	493	-	-
Mantris Gestão em Saúde Corporativa Ltda.	569	134	-	-	436	112	-	-
Nobeloy S.A.	477	475	-	-	3	348	-	-
Patologia Clínica Dr. Geraldo Lustosa Cabral Ltda.	1,450	730	-	-	2,244	868	-	-
Previlab Análises Clínicas Ltda.	20,475	11,254	-	-	10,806	9,185	-	-
Ruggeri & Piva Ltda.	2,881	1,935	-	-	1,828	1,483	-	-
Salomão e Zoppi Serviços Médicos e Participações S.A.	22,610	12,933	4,582	-	34,613	21,927	4,582	-
São Marcos – Saúde e Medicina Diagnóstica S.A.	3,384	3,534	-	-	10,247	15,515	-	-
Valeclin Laboratório de Análises Clínicas Ltda.	7,015	6,025	6,306	4,967	1,406	2,350	16,613	4,918
	101,354	**67,484**	**12,093**	**6,283**	**185,099**	**156,144**	**28,530**	**6,579**

(a) Property rental transactions.

Related party transactions presented above are carried out at cost and are eliminated in the consolidated financial statements.

b) Loan agreements between the Company and its subsidiaries

	Remuneration	Maturity	12/31/2024	12/31/2023
Loan agreement				
Centro de Diagnóstico Boris Berenstein Ltda.	120% CDI	06/02/2025	27,217	24,045
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	120% CDI	10/06/2025	204	180
DASA Real Estate Empreendimentos Imobiliários Ltda.	120% CDI	03/20/2025	5,113	-
DB Genética Serviços Laboratoriais Ltda.	120% CDI	07/10/2026	69,701	65,131
Fernando Henriques Pinto Junior & Cia Ltda.	120% CDI	11/25/2026	8,883	7,849
Ímpar Serviços Hospitalares S.A.	120% CDI	07/22/2027	143,081	-
Instituto de Hematologia de S.J.R Preto Ltda.	120% CDI	01/19/2027	6,493	4,751
Laboratório Bioclínico MS Ltda.	120% CDI	11/29/2027	619	-
Laboratório de Anatomia Patológica e Citopatologia São Camilo Ltda.	120% CDI	09/20/2027	317	-
Laboratório Nobel S.A. and subsidiaries	120% CDI	10/25/2025	8,003	3,073
Mantris Gestão em Saúde Corporativa Ltda	120% CDI	09/30/2027	13,561	-
Santa Celina Participações S.A.	120% CDI	01/29/2027	179,664	131,091
São Marcos – Saúde e Medicina Diagnóstica S.A. and subsidiaries	120% CDI	09/30/2027	5,638	-
Valeclin Laboratório de Análises Clínicas Ltda.	120% CDI	09/25/2027	11,271	-
			479,765	**236,120**

The loan agreements between the Company and its subsidiaries generated financial income, eliminated upon consolidation, of R$ 44,380 for the year ended December 31, 2024 (R$ 30,891 on December 31, 2023).

(In thousands of reais, unless otherwise indicated)

c) Dividends and interest on own capital receivable by DASA from its subsidiaries

	12/31/2024	12/31/2023
Centro de Diagnóstico Boris Berenstein Ltda.	5,978	-
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	883	1,074
CPClin - Centro de Pesquisas Clínicas Ltda.	602	3,143
DASA Real Estate Empreendimentos Imobiliários Ltda	-	2,463
DB Genética Serviços Laboratoriais Ltda.	265	-
Ímpar Serviços Hospitalares S.A.	-	91,215
Instituto de Hematologia de S.J.R Preto Ltda.	-	1,951
Laboratório Bioclínico MS Ltda.	-	7,163
Laboratório Chromatox Ltda.	63	14,618
Laboratório Deliberato de Análises Clínicas Ltda.	-	2,589
Patologia Clínica Dr. Geraldo Lustosa Cabral Ltda.	4,824	-
Previlab Análises Clínicas Ltda.	13,205	11,735
Ruggeri & Piva Ltda.	-	4,856
Valeclin Laboratório de Análises Clínicas Ltda.	45	1,739
	25,865	**142,546**

d) Related parties – Current assets

In 2023, the Company implemented a corporate expense transfer process, from the Parent Company to the subsidiaries. These on lendings involve corporate expenses that the Parent Company initially assumes and then repasses to the subsidiaries. The amounts were recorded as related parties in current assets, totaling R$ 1,909,944 (R$ 1,190,438 on December 31, 2023).

Furthermore, the Company shares specialized medical services with its subsidiary Salomão e Zoppi Serviços Médicos e Participações S.A., which were recorded under related parties in current assets, in the amount of R$ 63,450 (R$ 69,121 on December 31, 2023).

e) Management remuneration

Expenses related to the remuneration of key management personnel, including the Board of Directors, the Audit Board and the Statutory Executive Board, recognized in the statement of income, were:

	12/31/2024			12/31/2023		
	Board of Directors	Statutory Executive Board	Total	Board of Directors	Statutory Executive Board	Total
Fixed remuneration (Salary/Directors' fees)	9,992	20,505	30,497	8,936	14,484	23,420
Variable remuneration	-	32,193	32,193	-	15,237	15,237
Share-based payments	4,106	6,816	10,922	-	2,974	2,974
TOTAL	**14,098**	**59,514**	**73,612**	**8,936**	**32,694**	**41,630**
Benefits	-	769	769	-	371	371
Number of members (average)	7	11		7	13	

Fixed remuneration includes salaries and fees, vacations, compulsory bonuses and Christmas bonuses, social security contributions (INSS - the Company's share).

The variable remuneration includes short-term and long-term performance, hiring, and termination bonuses. The benefits include medical assistance, meal vouchers, food vouchers, and allowance.

Changes in the managements' stock option plans are presented in Note 21.

(In thousands of reais, unless otherwise indicated)

f) Other related party balances

Operations among related parties are carried out at usual market values, terms and rates as agreed among the parties, in effect on the respective dates as follows:

Related party	Activity	Balances payable at 12/31/2024	Balances payable at 12/31/2023	Expenses at 12/31/2024	Expenses at 12/31/2023
3G Empreendimentos E Participações Ltda.	Own real estate purchase and sale	-	(606)	(7,879)	(6,038)
AEC Consultores Ltda.	Consulting and advisory	(17)	(17)	(281)	(254)
Agaesse Serviços Ltda.	Service provider	(57)	(57)	(684)	(627)
Amar Admin. de Bens Próprios Ltda.	Real estate rent	(24)	(37)	(288)	(439)
BFL Empreendimentos Imobiliários Ltda.	Real estate rent	(222)	(213)	(2,647)	(2,538)
César Antonio Biazio Sanches	Real estate rent	(8)	(7)	(96)	(92)
Conexa Saúde Serviços Médicos Ltda.	Service provider	(1)	(18)	(93)	(478)
Connectcom Teleinformática Comércio e Serviços Ltda.	Service provider	-	(3)	(9)	(55)
Copa Serviços De Coleta E Diagnósticos Ltda.	Service provider	(122)	(118)	(1,649)	(1,583)
Coupa Software Brasil Ltda.	Service provider	-	-	(2,210)	-
DMG Laboratório Médico Ltda.	Service provider	(124)	(113)	(1,542)	(1,452)
Ecolimp Sistemas de Serviços Ltda.	Service provider	(6,843)	(8,031)	(48,115)	(43,332)
ECRD Serv. Médicos de Radiologia Ltda.	Provision of medical services	-	-	(2,559)	(2,128)
Edan Serviços De Coleta.	Franchise agreement	(147)	(94)	(1,979)	(1,016)
Effortech Engenharia & Incorporações Ltda.	Engineering services	-	-	-	(93)
Essijota Serv. de Coleta e Diag. Ltda.	Franchise agreement	(339)	(204)	(3,550)	(2,493)
Fernandes Oncologia	Outpatient medical activity	-	(196)	(2,475)	(2,573)
FL Pediatria e Puericultura Ltda.	Outpatient medical activity restricted to consultations	-	(3)	(264)	(117)
HRO - Hospital de Referência Oftalmológica Ltda.	Emergency room activities	(20)	(8)	(221)	(165)
José de Oliveira Domingues	Real estate rent	(20)	(12)	(235)	(162)
Link Consult. em Medicina Diag. Ltda.	Consulting and advisory	(17)	(17)	(273)	(248)
Localiza Rent a Car S.A.	Vehicle rental	(17)	(41)	(319)	(313)
Luminamd Capacitação e Treinamento Ltda.	Training	-	-	-	(5)
Mega Copa Serviços de Coleta e Diagnósticos Ltda.	Service provider	(69)	(64)	(773)	(714)
Meier Serviços De Coleta E Diagnósticos Ltda.	Service provider	(38)	(53)	(468)	(513)
Patrys Investimentos Imobiliários Ltda.	Real estate rent	(15,871)	(15,569)	(121,409)	(92,946)
Pechincha Serviços de Coleta e Diagnósticos Ltda.	Service provider	(159)	(138)	(1,787)	(1,688)
Pesmed – Pesq. e Serv. Médicos Ltda.	Provision of medical services	-	-	(839)	(656)
Phd Serviços De Coleta Ltda.	Service provider	(113)	(116)	(1,586)	(1,222)
Prime Health Serv. Médico	Outpatient medical activity restricted to consultations	-	-	(234)	(107)
PTR14 Investimentos Imobiliários S.A.	Real estate rent	(2,129)	(2,129)	(27,678)	(21,291)
PTR7 Investimentos Imobiliários Ltda.	Real estate rent	(1,918)	(1,918)	(23,020)	(23,064)
RMR Ressonância Magnética Ltda.	Provision of medical services	-	-	(2,388)	(2,332)
Seven Seas Partner Saúde e Prev. Ltda.	Service provider	(71)	(86)	(1,180)	(1,005)
Signo Properties Invest. Imobiliários Ltda.	Real estate rent	(358)	(358)	(4,648)	(3,940)
Ultrascan Serviços de imagem Ltda.	Provision of medical services	-	-	(101)	(117)
VIDA - Posto de Coleta Ltda.	Franchise agreement	(130)	(95)	(1,400)	(1,145)
VK Saúde	Activities of healthcare professionals	-	-	(819)	(1,369)
		(28,834)	**(30,321)**	**(265,698)**	**(218,310)**

After the third quarter of 2024, the Company became aware of the current control structure of CM Hospitalar S.A. and, based on the opinion of legal and accountant external advisors, concluded that CM Hospitalar S.A. does not qualify as a related party, as defined in CPC 5 – Related Party Disclosure.

Some amounts presented in the table above as of December 31, 2023, have been changed for better comparability with the amounts presented in 2024.

(In thousands of reais, unless otherwise indicated)

31 Insurance coverage

On December 31, 2024, the total insurance coverage was R$2,817,882, and R$ 689,682 for loss of profits, R$ 903,200 for property damage and R$ 10,000 for professional civil liability, R$ 150,000 for professional liability of Directors & Officers (D&O), and R$ 1,065,000 to tax, social security, labor and civil provision, among others.

32 Discontinued operations

The assets and liabilities of Nobeloy, Optiren, Genia Argentina, Genia Chile, and Genia Colombia are presented as discontinued operations, following a decision to discontinue these businesses by DASA Group's Management and shareholders. Operations are scheduled to fully cease in 2025.

The balance sheet and statement of income for discontinued operations is presented below:

12/31/2024

	Nobeloy	Optiren	Genia Argentina	Genia Chile	Genia Colombia	Eliminations	Total
CURRENT ASSETS							
Cash and cash equivalents	-	-	5,106	63	-	-	5,169
Trade accounts receivable	108	9,375	660	245	-	-	10,388
Inventories	-	-	603	-	-	-	603
Recoverable taxes	984	-	37	2	-	-	1,023
Prepaid expenses	-	-	-	24	-	-	24
Other receivables	264	281	1,203	-	-	-	1,748
TOTAL CURRENT ASSETS	**1,356**	**9,656**	**7,609**	**334**	**-**	**-**	**18,955**
NON-CURRENT ASSETS							
LONG-TERM ASSETS							
Deferred taxes	-	-	3,801	-	-	-	3,801
Judicial deposits	66	-	-	28	-	-	94
Related parties	4,967	553	-	-	-	(5,520)	-
Other receivables	-	-	-	-	-	-	-
NON-CURRENT RECEIVABLES	**5,033**	**553**	**3,801**	**28**	**-**	**(5,520)**	**3,895**
Investments	-	6	-	-	-	-	6
Property and equipment	-	-	1,986	71	-	-	2,057
TOTAL NON-CURRENT ASSETS	**-**	**6**	**1,986**	**71**	**-**	**-**	**2,063**
TOTAL ASSETS	**6,389**	**10,215**	**13,396**	**433**	**-**	**(5,520)**	**24,913**
CURRENT LIABILITIES							
Bank loans	300	-	-	-	-	-	300
Suppliers	761	14	4,537	105	-	-	5,417
Social charges and labor obligations	820	35	247	444	-	-	1,546
Income tax and social contribution	97	-	4,265	11	-	-	4,373
Taxes and contributions payable	-	-	-	-	-	-	-
Advance from clients	-	-	-	-	-	-	-
Other accounts payable and provisions	8,849	4	12,966	597	-	(13,513)	8,903
TOTAL CURRENT LIABILITIES	**10,827**	**53**	**22,015**	**1,157**	**-**	**(13,513)**	**20,539**
NON-CURRENT LIABILITIES							
Deferred taxes	-	-	15	-	-	-	15
TOTAL NON-CURRENT LIABILITIES	**-**	**-**	**15**	**-**	**-**	**-**	**15**
TOTAL LIABILITIES	**10,827**	**53**	**22,030**	**1,157**	**-**	**(13,513)**	**20,554**

(In thousands of reais, unless otherwise indicated)

	Nobeloy	Optiren	Genia Argentina	Genia Chile	Genia Colombia	Eliminations	Total
Net operating revenue	-	-	6,681	3,293	-	(97)	9,877
Cost of services rendered (a)	(252)	(67)	(6,473)	(557)	-	2,929	(4,420)
Gross profit (loss)	**(252)**	**(67)**	**208**	**2,736**	**-**	**2,832**	**5,457**
General and administrative expenses (a)	(105)	(51)	(3,541)	(3,340)	-	-	(7,037)
Other income and (expenses), net	-	-	6	744	-	-	750
Profit (loss) before net financial expenses, taxes	**(357)**	**(118)**	**(3,327)**	**140**	**-**	**2,832**	**(830)**
Financial income	164	1,625	5,073	50	-	-	6,912
Financial expenses	(19)	(12)	(4,779)	(45)	-	-	(4,855)
Financial income (expenses), net	**145**	**1,613**	**294**	**5**	**-**	**-**	**2,057**
Profit (loss) before income tax and social contribution	**(212)**	**1,495**	**(3,033)**	**145**	**-**	**2,832**	**1,227**
Income tax and social contribution	(29)	-	780	-	-	-	751
Profit (loss) for the year	**(241)**	**1,495**	**(2,253)**	**145**	**-**	**2,832**	**1,978**

(a) Includes amortization and depreciation costs and expenses of R$ 727.

12/31/2023

	Nobeloy	Optiren	Eliminations	Total
CURRENT ASSETS				
Cash and cash equivalents	305	57	-	362
Trade accounts receivable	967	7,329	(8,125)	171
Recoverable taxes	899	-	-	899
Other receivables	205	218	-	423
TOTAL CURRENT ASSETS	**2,376**	**7,604**	**(8,125)**	**1,855**
NON-CURRENT ASSETS				
LONG-TERM ASSETS				
Judicial deposits	58	-	-	58
Related parties	2,853	484	3,337	-
NON-CURRENT RECEIVABLES	**2,911**	**484**	**(3,337)**	**58**
Investments	-	5	-	5
TOTAL NON-CURRENT ASSETS	**-**	**5**		**5**
TOTAL ASSETS	**5,287**	**8,093**	**(11,462)**	**1,918**
CURRENT LIABILITIES				
Suppliers	587	7	-	594
Taxes and contributions payable	971	472	-	1,443
Social charges and labor obligations	636	29	-	665
TOTAL CURRENT LIABILITIES	**2,194**	**508**	**-**	**2,702**

(In thousands of reais, unless otherwise indicated)

	Nobeloy	Optiren	Eliminations	Total
Net operating revenue	7,207	8,438	(7,139)	8,506
Cost of services rendered (b)	(6,262)	(10,282)	2,382	(14,162)
Gross income	**945**	**(1,844)**	**(4,757)**	**(5,656)**
General and administrative expenses (b)	(6,036)	(7,101)	-	(13,137)
Other income and (expenses), net	(1,800)	(6,571)	-	(8,371)
Loss before net financial expenses, taxes	**(6,891)**	**(15,516)**	**(4,757)**	**(27,164)**
Financial income	(138)	(356)	-	(494)
Financial expenses	(108)	(50)	-	(158)
Financial income (expenses), net	**(246)**	**(406)**	**-**	**(652)**
Loss before income tax and social contribution	**(7,137)**	**(15,922)**	**(4,757)**	**(27,816)**
Income tax and social contribution	(413)	-	-	(413)
Loss for the year	**(7,550)**	**(15,922)**	**(4,757)**	**(28,229)**

(b) Includes amortization and depreciation costs and expenses of R$ 1,715.

33 Cash flow supplementary information

The statements of cash flows are prepared in accordance with CPC 03 (R2)/IAS 07 - Statement of Cash Flows and presented using the indirect method.

The Company and its subsidiaries present interest paid on loans, financing, debentures and leases in operating activities and dividends received in investing activities.

The main non-cash transactions were:

	Note	Parent Company		Consolidated	
		12/31/2024	12/31/2023	12/31/2024	12/31/2023
Acquisitions of property and equipment and intangible assets:					
Total acquisitions of property and equipment and intangible asset	12 and 13	324,914	515,484	546,885	959,203
With cash effect		316,957	369,439	538,499	811,249
No cash effect		7,957	146,045	8,386	147,954
Non-cash leases - Additions and remeasurements	11				
Right of use		267,468	136,006	475,604	543,481
Lease liabilities		(268,377)	(134,694)	(475,604)	(543,481)

34 Subsequent events

(a) Association agreement between DASA and Amil - update

On February 4, 2025, DASA and Amil approved an amendment to the Association Agreement to, among other aspects, (i) change the amount of Ímpar's net debt at the transaction completion from R$ 3,850,000 to R$ 3,500,000, including net financial debt, the balance of derivative transactions, accounts payable for acquisitions and tax installment payment; and (ii) change the amount of net debt that will be contributed at the closing of the transaction, together with Amil's assets, from zero (0) Reais to cash of R$ 350,000. As a result of this change, net debt, after the transaction closing, is expected to be R$ 3,150,000.

On February 14, 2025, Impar issued three million (3,000,000) simple debentures, not convertible into shares, with real guarantee, unsecured, in a single series, of the second (2nd) issue, with a nominal unit value of one thousand reais (R$ 1,000.00), totaling, on the issue date, R$ 3,000,000. The amounts were received by Impar on February 26, 2025.

On February 26, 2025, DASA's Extraordinary General Meeting approved the merger of Ímpar's spun-off assets by the Company, comprising the assets and operations excluded from the scope of the Association Agreement. The transaction approved at the meeting was subject to ratification by the Company's Board of Directors of Ímpar's compliance with the net indebtedness assumption provided for in the Association Agreement documents and verification by the same Board of Directors of the implementation of the conditions precedent agreed within the scope of the Association Agreement, at a meeting in which compliance with the aforementioned conditions precedent and verification of compliance with the aforementioned indebtedness assumptions are cumulatively verified. The meeting's agenda also included the amendment and consolidation of DASA's Bylaws to reflect the new value and number of shares into which the Company's share capital is divided as a result of the recently approved capital increase.

On February 28, 2025, the capital of Ímpar was reduced by R$ 2,075,000.

(b) Hedge accounting – fair value hedge

In November 2022, May 2023 and February 2024, DASA issued debentures with fixed-rate and IPCA+ financial charges. When these debentures were issued, DASA contracted hedge instruments, exchanging the fixed-rate and IPCA+ financial charges for CDI+ (Note 29.a.3). Upon initial recognition of these debentures, the hedge instruments were not designated as hedge accounting.

In the first quarter of 2025, the management upon reviewing the impacts of marking to market the fair value of the hedge instruments in the statement of income, identified an accounting mismatch from the classification of debentures as liabilities measured at amortized cost and at fair value of the hedge instrument of these debentures. Consistent with the Company's policy, management decided to designate the protection instruments as fair value hedge, classifying the debentures as a financial liability measured at fair value through profit or loss. Accordingly, the effects on the financial profit (loss) are expected to reflect the Company's exposure to the CDI rate.

***

Lício Tavares Ângelo Cintra
Chief Executive Officer

André Covre
Chief Financial and Investor Relations Officer

Evandro Luis Rezera
Chief Tax Controlling Officer

Luiz Carlos Miranda
Controllership Senior Manager
CRC 1SP168723/O-8